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Abstract 
Ganoderma lucidum (Ling Zhi,靈芝） is one of the most 
precious medicinal drugs in Chinese herbal medicine, which is 
famous for its widespread medicinal benefits and putative anti-
aging actions. Along wi th most Chinese medicinal drugs, the 
pharmacological actions of Ganoderma lucidum are thought to be 
modulatory on body functions. This thesis attempts to further the 
study on the biological activities of Ganoderma lucidum w i th 
special emphasis on its modulatory actions on antioxidant defense 
system and immune system, which are especially important for 
body defense against disease. 
The present study shows that a negatively-charged and 
carbohydrate-r ich f ract ion (GL2) f rom Ganoderma lucidum 
exhibited both an antioxidant activity and an immunomodulatory 
activity. Oral pretreatment wi th GL2 was found to protect mice 
f rom hepatotoxicity induced by carbon tetrachloride, while in 
Wtro co-incubation of murine isolated hepatocytes wi th GL2 also 
offered protect ion against phorone- and menadione-induced 
hepatocellular damage. The results suggest that GL2 may exert its 
effect by enhancing hepatic g lutath ione status. In the 
immunological aspect, GL2 was found to contain a B cell mitogenic 
principle which may be a sulphated glycan. As similar to other B 
cell mitogens, GL2 augments the humoral response to sheep red 
blood cells in mice, as evidenced by the increase in plaque 
forming cells, when i t was given intraperitoneally 30 minutes 
prior to immunization. 
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The Role of Natural Products in Modern Medicine 
Long before modern medicine has emerged, people f rom 
different cultures had developed their own herbal medicine which 
was based exclusively on what they could f ind in their habitats. 
With innumerable brave trials and keen observations, repertoires 
of natura l products w i th medicinal properties have been 
established. Although how these drugs work are not known, their 
effectiveness in healing many diseases and in ameliorating many 
cases of body mal-functioning has won the applause of modern 
medicine. We just appreciate that nature has granted us wi th such 
a large chemical variety which flourishes the possibilities of 
pharmacological applications. Thus, what modern medicine is 
going to do w i th these natura l products are qual i tat ive 
characterization. Instead of using ambiguous terms to describe the 
medicinal properties of natural products, we try to characterize 
the drugs wi th biological activities, and then sort out the active 
principles wi th respect to chemical identities. Thereafter a series 
of pharmacological studies can be followed, and they wi l l enable 
the optimal use of natural products in the treatment of various 
patho-physiological conditions. Moreover, new pharmacological 
activities may be discovered, which is especially important in the 
design of treatments that are not wel l-handled by modern 
medicine, such as AIDS and cancer therapy. Al l in all, i t comes the 





1.1 Historical background of Ling Zhi (靈芝） 
Ling Zhi, now identi f ied as the fungus Ganoderma lucidum 
(Lyess. ex FR.) KARST (Polypolaceae), is one of the most precious 
medicinal drugs in Chinese herbal medicine. It was f irst recorded 
i n the Shen Nung，s Herbal (神農本草經） f rom 2000 years ago, 
where Ling Zhi was classified as the superior class of herbal drugs 
(Zhao, 1987). According to the Toaist，s idea and some legendary 
accounts, Ling Zhi was regarded as an elixir of longevity and a 
panecea for all types of disease (Willard, 1990). In reality, many 
famous Chinese herbalists included Ling Zhi in their compendia of 
medicinal materials, and all of them stated that Ling Zhi can 
actually be beneficial to many diseases (Zhao and Zhang, 1992). It 
is widely-accepted that the widespread medicinal benefits of Ling 
Zhi are due to the nourishment of spirit, the strengthening of our 
body functions and the enhancement of our body defense. A l l 
these consolidate into an idea of "Fu Z h e n g " ( 扶正 ) t h e r a p y 
(Wil lard, 1990). A l though many ancient concepts about drug 
action are not supported by scientific evidence, the idea of "Fu 
Zheng" has found a way to metamorphose into a new concept in 
modern medicine. The "Fu Zheng" concept states that disease only 
prevails when the body defense ( termed as "Zheng Qi " ,正氣） i s 
weak or insuff ic ient. Thus i f we can f ind a way to increase or 
maintain the sufficiency of body defense, we wi l l be healthy and 
free of disease. In this sense, the strategy of combating disease 
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is preventive and modulatory, rather than therapeutic. From the 
standpoint of modern medicine, the term "Zheng Qi" can be 
interpreted as a sufficiency of two major body defense systems: 
the immune system and the antioxidant defense system. Although 
i t has not been str ingent ly demonstrated that enhanced 
immunocompetence and antioxidant defense wi l l lead to a 
disease-free state, numerous studies have shown that diseases are 
often accompanied with weakened immunocompetence (Abbas et 
aly 1991) and antioxidant defense (Halliwell and Gutteridge,1989). 
In addition, since therapeutic strategies targeted at pathogen/risk 
factor- induced physiological changes become less and less 
effective, particularly in cases of cancer and antibiotic resistance, 
i t makes a lot of sense to try an alternative way to enhance 
our body defense. Because Ling Zhi is a "Fu Zheng" drug wi th very 
high potency, i t is very possible that i t produces its medicinal 
effects main ly through enhancing immunocompetence and 
strengthening antioxidant defense. While recent studies on Ling 
Zhi have shown some biological activities relevant to this 
proposit ion (Bai, 1989), the work of this M. Phil, thesis aims to 
fur ther the research on Ling Zhi by exploring the possible 
involvement of immunomodulatory and antioxidant actions in its 
biological activities. 
In the subsequent sections, the biological description of Ling 
Zhi wi l l be introduced first. Then a brief review on the chemical 
constituents, biological activities and medicinal properties of Ling 
Zhi wi l l be given. Lastly, the relationship between the sufficiency 
of body defense and the susceptibility to disease wi l l be discussed 
w i th an overview on the funct ion of the immune system and 
antioxidant defense system. 
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1.2 Biological description of Ling Zhi 
According to the ancient archives, the term Ling Zhi was referred 
to more than one k ind of fungi, including Ganoderma lucidum 
(赤芝 ) a n d Ganoderma japonicuni (紫芝）（Zhao et ai,1981). I t is 
now generally agreed that Ganoderma lucidum is the genuine Ling 
Zhi according to most archives. Ganoderma lucidum belongs to the 
class basidiomycetes, in which all the members fo rm conspicuous 
f ru i t ing bodies to distr ibute spores. Al though the colours and 
shapes of f ru i t ing bodies are important clues for identif ication of 
Ganoderma species, i t has been documented that colours and 
shapes of Ganoderma species change according to environmental 
conditions and growth stages (Chen and Jiang, 1980). For example, 
the frui t ing bodies of Ganoderma lucidum that we f ind in the open 
environment are usually stipiate-pileate wi th surface of the stripe 
and pileus covered wi th a r ich brown natural lacquer (see Exhibit 
1). However, i n places where l ight intensity is low, such as mines, 
the scarce of l ight induces the format ion of strange antler-l ike 
f ru i t ing bodies, w i th small ferti le patches confined to the extreme 
tips of the branches (Talbot, P. H. B., 1971). The antler fo rm is so 
di f ferent that another special term is used, Ant ler Zhi (鹿角芝） 
(see Exhibit 2)(Chang eta i , 1980). However, i t is sti l l regarded as 
Ganoderma lucidum, and i t might be the form of Chi Zhi described 
by the great herbal ist Li Shi Chen ( 李 時 珍 ） i n his famous 
Compendium of Material Medica (本草綱目）(Li，Ming dynasty). 
Whatever the forms they assume, the f r u i t i n g bodies of 
Ganoderma lucidum generally possess leathery skin in reddish 
brown wi th d im gloss, while the stalks are dark brown wi th glaze. 
4 
Exhibit 1 Ganoderma lucidum wi th circular pileus (found on the 
campus of CUHK) 
_ 
Exhibit 2 Ganoderma lucidum wi th antler-like pileus (purchased 
f rom an authenticated source in South Korea) 
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Wild Ganoderma lucidum is saprophytic on roots and dead trunks 
of oak and other broad-leaved trees, and it grows mainly in the 
temperate zone (Zhao and Zhang, 1992). As the yield of wi ld 
Ganoderma lucidum is very low, only rich people in ancient China 
could afford it. Today, Ganoderma lucidum is being produced by 
artif icial cultivation and submerged fermentation (Cheng, 1993), 
and both circular pileus (conventional) and antler forms are 
available in the market. 
1.3 Chemical composition of Ganoderma lucidum 
Like all other fungi, extracts f rom Ganoderma lucidum 
contains components of fungal cell wall and membrane such as 
ergosterols, chitins and p-glucans. Proteins, carbohydrates, sugar 
alcohol (e.g. D-mannitol), nucleosides (e.g. adenosine) and alkaloids 
(e.g. betaine) are also present in significant amounts. Of particular 
interest is the bitter triterpenoids and the matrix polysaccharides, 
which make Ganoderma lucidum special in chemical terms. It has 
been demonstrated that most of the pharmacological properties of 
Ganoderma lucidum are associated with the triterpenoids and the 
polysaccharides (Jong and Birmingham, 1992). 
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1.3.1 The triterpenoids 
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Figure 1.1 Lanostane tr i terpenoid skeleton (adapted f rom Lin et 
a7,1988) 
Bitter taste has long been related to good therapeutic values 
according to tradit ional thoughts in Chinese medicine. Currently, 
about 100 different triterpenoids (Figure 1.1) are known to occur 
in Ganoderma lucidum alone, and most of them are bitter in taste. 
The vast major i ty are ganoderic ( C 3 0 ) and lucidenic ( C 2 7 ) acids 
(Figure 1.2), but other tr i terpenoids such as ganodermic acids, 
ganoderenic acids, lucidone, ganoderal and ganoderol are also 
present. The triterpenoids can vary f rom strain to strain and f rom 
one growth stage of the fungus to another through side-chain 
cleavage and skeletal oxidation (Jong and Birmingham, 1992). But 
their functions in the fungus is stil l unknown. Perhaps they might 
play a role similar to that of cholesterol in animal cells, since they 
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Figure 1.2 C27 and C30 triterpenoids (adapted f rom Nishitoba et 
al, 1984) 
1.3.2 Matrix polysaccharides 
Matrix polysaccharides are water-soluble components of the 
fungal cell wall, which f i l l up the space between the chitinous 
water-insoluble cell wall and the plasma membrane (Kuhn et a l , 
1990). 
A large number of water-soluble polysaccharides have been 
fractionated f rom the fruit ing body of Ganoderma lucidum. They 
include a- and p-glucans, fucogalactans, mannofucogalactans and 
acidic p-glucans.'The neutral p-l,3-glucans are famous for their 
anti-tumour activity against sarcoma 180 solid tumour in mice, 
and they are also found in many other types of fungi in addit ion 
to Ganoderma lucidum. The remaining polysaccharides are less 
characterized and most of them are confined to Ganoderma 
lucidum only. Some of them are indeed proteoglycans or derived 
from glycoproteins, the others are complex heteropolysaccharides. 
The biological activities of these polysaccharides are very diverse. 
Together with the triterpenoids and other active components, they 
lend support to the basis of mult iple pharmacological activities 
ascribable to Ganoderma lucidum (Jong and Birmingham, 1992). 
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1.4 Medicinal properties and biological activities 
Since Ganoderma lucidum and its associated products are 
widely used without thorough understanding of their mechanisms 
of actions, i t is necessary to define tlie biological activities in order 
to substantiate its medicinal properties. Biological activities are 
those drug actions af f i rmed by experimental studies, but 
pharmacological efficacy in human beings are of ten not 
determined. Medicinal properties, however, are the "claimed" drug 
actions suggested by the archives or certain successful clinical 
trials, usually the mechanisms of actions are unknown. For 
example, the traditional indications are some guidance for the use 
of drugs, but they have never offered any convincing explanation 
for the drug actions. Therefore, the studies of biological activities 
help to justify the known medicinal properties and to discover the 
new ones. Nervertheless, the "claimed" medicinal properties can 
provide a direction for the search of biological activities. 
1.4.1 Medicinal properties 
In Chinese medical terms, Ganoderma lucidum is "bland in 
taste, warm in nature, and attributive to heart, spleen (referring 
to digestive funct ion), lung, l iver and k idney". Tradi t ional 
medicine archives also state that i t serves to "tranqui l l ize the 
mind, enrich vi tal energy and blood, eliminate phlegm, relieve 
cough and dyspnea". Though these descriptions are ambiguous, 
current f indings about the therapeutic values of Ganoderma 
lucidum are highly consistent wi th what the archives describe, 
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such as those of sedative and analgesic actions, hepatoprotection, 
h y p o g l y c a e m i c a c t i v i t y , h y p o t e n s i v e a c t i v i t y , 
hypocholesterolaemic activity and anti-tussive action (〇u，1981). 
Thus, i t has been used by patients suffering f rom coronary heart 
disease, chronic bronchitis and hepatitis in China and South East 
Asia. Apart f r o m these major medicinal uses, Japanese has 
patented some medicinal products w i th Ganoderma lucidum 
extracts as the active ingredients, such as a fermentat ion 
preparation for the treatment of patients wi th Alzheimer's disease 
and a hair tonic (Jong and Birmingham, 1992). 
1.4.2 Biological activities 
1.4.2.1 Anti- tumour activity 
Polysaccharides f rom Ganoderma lucidum are found to be 
responsible for its ant i - tumour act iv i ty. The tumour models 
having been studied include sarcoma 180 solid tumour i n mice 
(Miyazaki and Nishij ima, 1981) and Lewis lung carcinoma i n 
syngeneic mice (Furusawa et ai, 1992). At least four d i f ferent 
types of polysaccharides have been characterized: a branched 
arabinoxy log lucan (GL-1); a p ro te in -bound polysacchar ide 
composed of galactose, glucose, xylose and 16 amino acids; a 
neutral heteroglycan composed of mannose，fucose and xylose and 
several p-glucans of di f ferent molecular sizes and minor sugar 
components (Jong and Birmingham, 1992). The p-glucans are the 
wel l -s tudied polysaccharides among the others (Jong and 
Donovick, 1989). The anti- tumour activity is found to depend on 
both the solubi l i ty of the glucans in water and their molecular 
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size. With the higher solubility in water and the smaller molecular 
size, the greater anti-tumour activity could be obtained. The 
min imum common unit of anti-tumour active glucans of various 
basidiomycetes, including Ganoderma lucidum, was determined by 
Miyazaki (1983) to be a C-6 branched 1—>3)D-glucopyranosyl 
residue. It is inferred that the ant i - tumour act iv i ty of the 
polysaccharides may be mediated by its effects on the host 
immunological functions (Jong and Birmingham, 1992). 
1.4.2.2 Enhancement of protein and nucleic acid synthesis 
A polysaccharide from Ganoderma lucidum, namely De, was 
found to increase protein synthesis in liver and bone marrow in 
mice. D6 also enhanced both DNA and RNA synthesis in bone 
marrow, but in liver, only RNA synthesis, but not DNA synthesis, 
was st imulated. This may be at t r ibuted to the act ion of 
Ganoderma lucidum in enhancing body defense, since bone 
marrow is the place where lymphocytes and leukocytes are 
derived f rom and liver is the major organ for detoxification (Jong 
and Birmingham, 1992). 
1.4.2.3 Effects on nervous system 
Extracts of Ganoderma lucidum were found to suppress 
spontaneous motor activity in mice, prolong barbital- induced 
sleeping time, prevent nicotine-induced convulsions and inhib i t 
pi locarpine-induced salivary secretion. The adenosine isolated 
from the extracts showed similar effects, thus i t may well be one 
, of the active components producing effects on nervous system. 
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Some researchers believed that the regulatory actions on nervous 
system may contribute to the increase in non-specific body 
resistance; however, there is sti l l no plausible physiological 
explanat ion for such a putat ive relat ionship (Jong and 
Birmingham, 1992). 
1.4.2.4 Effects on respiratory system 
Daily intragastric doses of a concentrated solution containing 
the mycelia of Ganoderma lucidum induced a regeneration of the 
bronchial epithelium. The aqueous extract of Ganoderma lucidum 
also showed significant anti-tussive and expectorant actions on 
induced cough. These findings agree with the traditional indication 
of Ganoderma lucidum for lung diseases (Jong and Birmingham, 
1992). 
1.4.2.5 Effects on cardiovascular system 
Ganoderma.lucidum has been shown to produce mult iple 
effects on cardiovascular system, including the direct effect on 
cardiac functions, hypotensive activity, hypocholesterolaemic 
act iv i ty , hypoglycaemic act iv i ty and platelet aggregation 
inhibit ion. 
Both the ethanol extract and the polysaccharide fractions 
f rom Ganoderma lucidum have been demonstrated w i th a 
cardiotonic effect, while the crude extract was effective i n 
increasing the tolerance to hypobaric and normobaric hypoxia 
(Lee and Rhee, 1990). However, the abil i ty to increase coronary 
f low and lower coronary resistance and myocardial oxygen 
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consumption in cats and dogs is attr ibuted to the actions of 
alkaloids (Chen et a l , 1976). 
While the mechanism involved in the direct effect of 
Ganoderma lucidum components on heart is sti l l unknown, the 
hypotensive activity and the hypocholesterolaemic activity are 
believed to be based on enzyme inhib i t ion. Regarding the 
hypotensive activity, 10 lanostane triterpenoids were identif ied 
and all exhibited inhib i tory action on angiotensin-converting 
enzyme, thereby lowering blood pressure (Morigiwa etal, 1986). 
For the hypocholesterolaemic activity, triterpenoids can lower 
blood cholesterol level by inhib i t ing cholesterol synthesis by 
virtue of their structural resemblance to cholesterol (Komoda et ai, 
1989). 
For the hypoglycaemic activity, polysaccharides play a 
crucial role. It has been shown that ganoderan A and ganoderan B, 
which are isolated f rom water extract of Ganoderma lucidum， 
were the active principles mediating a hypoglycaemic effect. The 
lowering of blood glucose by these polysaccharides is achieved by 
increasing the plasma insulin level and accelerating the glucose 
metabolism, presumably by potentiating the activities of hepatic 
enzymes which are involved in carbohydrate metabolism (Hikino 
etal, 1985). 
For the inhib i t ion of platelet aggregation, adenosine was 
identif ied as the active principle, and this may contribute to the 
reduction of stroke (Shimizu et al，1985; Wang et ai, 1989; Wang 
et al 1991). Taken together, the combined action of Ganoderma 
lucidum on the cardiovascular system ensures good blood supply 
wi th sufficient nutrients, which again can be a footnote for the 
traditional indication "enrich vital energy and blood”. 
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1.4.2.6 Effects on immune system 
As mentioned earlier, the anti-tumour polysaccharides may 
act by modulating the immune system. However, how they act is 
s t i l l unclear. Recent studies have character ized the 
immunomodulatory polysaccharides in two aspects. Firstly, i t is 
the polysaccharide GL-B which promotes the product ion of 
interleukin 2 in mixed lymphocyte response (Lei and Lin, 1992), 
and increases the activity of DNA polymerase a of splenocytes in 
aged mice as compared to the young ones (Lei and Lin, 1993). 
Secondly, another polysaccharide component called BN3C which 
can enhance concanavalin A-induced murine T cell proliferation 
(Xie et a l , 1985). In addition to polysaccharides, proteins and 
tr i terpenoids f rom Ganoderma lucidum also contribute to 
immunomodulat ion. The protein LZ-8 was isolated f rom the 
myce l ia l extract and was f ound to be capable of 
haemagglutinating sheep red blood cells but not human red blood 
cells (Miyasaka era?，1992). LZ-8 could prevent the production of 
a systemic anaphylaxis reaction in mice. Its immunomodulatory 
actions are probably mediated through faci l i tat ing cellular 
interactions by enhancing the expression of adhesion molecules 
(Haak-Frendscho et al 1993). For the tr i terpenoids, i t was 
demonstrated that ganodermic acids A, B, C and D were 
physiologically active in inhibit ing histamine release f rom rat 
mast cells (Kohda, 1985). 
1.4.2.7 Hepatoprotection and detoxicaiit actions 
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Studies on hepatoprotection were mainly conducted using 
toxin-challenged animal models and cell cultures. The ethanol 
extract was identified as the active components in some reports, 
for example, ganodermic acid R and S were found to be highly 
anti-hepatotoxic in galactosamine-induced cytotoxicity in primary 
culture of rat hepatocytes (Hirotaiii, 1986)，while the crude water 
and ethanol extracts were shown to be effective in lowering the 
serum transaminase level in carbon-tetrachloride challenged rats 
and mice (Liu et al，1979). It is speculated that these 
hepatoprotective effects were conferred by putative antioxidant 
properties in Ganoderma lucidum. 
1.4.3 Summary 
It has been clearly shown that the medicinal properties of 
Ganoderma lucidum are contributed by compounds of diverse 
chemical nature. As one of the best "Fu Zheng” drugs, Ganoderma 
lucidum exerts its beneficial effects on most body functions, and 
this accords well with the traditional indication. 
1.5 The relationship between antioxidant defense/immune 
system and disease 
The immune system and antioxidant defense system work 
together to maintain a healthy state in our body. Antioxidant 
defense operates at sub-cellular level, in which a number of 
enzymes and antioxidant compounds are employed to control the 
levels of reactive oxygen species (R〇S). R〇S such as superoxide 
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anion, hydrogen peroxide, and hydroxyl radical are inevitably 
produced during the normal course of aerobic metabolism. These 
R〇S attack virtual ly all kinds of biomolecules and induce cellular 
injury (Koppenol, 1990; Cochrane, 1991). The defense against R〇S 
includes antioxidant system which scavenges R〇S directly and 
inactivates prooxidants, as well as repair systems which fix the 
oxidatively damaged cellular components. Oxidative stress is thus 
defined as the result of either a deficiency in antioxidant defense 
system and repair system or an increase in the production of R〇S 
which overwhelms the defense system (Sies, 1991). Major 
biological sources of R〇S are the electron transport chain in 
mitochondria, cytochrome P450, all oxidases and lipooxygenases 
and xenobiotic prooxidants. In some specialised cells such as 
phagocytes, R〇S are produced purposefully by NADPH oxidase to 
serve as a weapon against microorganisms. On the other hand, 
antioxidant defense is ubiquitous in all kinds of cells. Enzymes 
such as superoxide dismutase (SOD) and catalase direct ly 
inactivate ROS. Ascorbic acid (vit. C) and a-tocopherol (vit. E) 
serve as low molecular-weight antioxidant. Glutathione (GSH) also 
acts as a low molecular-weight antioxidant which is important in 
maintaining intracel lular thiols in their reduced forms , in 
regenerating vit. E, and in repairing peroxidized lipids together 
wi th GSH peroxidases. Since transition metal ions promote ROS 
I 
generation, sequestration of metal ions such as i ron and copper is 
also an important mechanism in antioxidant defense (Ross and 
Moldeus, 1990). Repair systems include enzymes for DNA repair, 
GSH peroxidases for repairing peroxidized lipids and proteases for 
recognizing oxidatively modified proteins (Davies, 1993). Al l these 
systems work co-operatively to antagonize oxidative stress. Any 
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decline in antioxidation funct ion wi l l lead to oxidative tissue 
damage which may result f rom l ip id peroxidat ion. L ip id 
peroxidation is an auto-accelerating process i f i t is unchecked. 
Thus antioxidant defense often acts at a preventive level to l imi t 
the extent of l ip id peroxidation, or otherwise the capacity of 
antioxidant would be exhausted i f l ip id peroxidation prevails 
(Rice-Evans and Burdon, 1993). In addition, the lost of metabolic 
integr i ty after oxidative challenge also l imits the metabolic 
support to the antioxidant defense. If the metabolic support of 
antioxidant defense is disrupted by means other than oxidative 
challenge, oxidative damage wi l l stil l be incurred since ROS are 
continuously generated in the cells (Lissi et aJ，1991). 
Therefore, when we consider a certain clinical condition in 
which severe oxidative damage is implicated, this may be a 
consequence of increased oxidative stress or a consequence 
secondary to cell death. Antioxidant therapy is useful in terms of 
therapeutic efficacy for the former case only (Bulkley, 1993). 
However, even though oxidative stress is not the primary cause of 
some clinical conditions, i t must play a role in promoting the 
progress of tissue injury, for example, the leakage of sequestered 
i ron f rom injured tissues can impose an oxidative stress to the 
neighbouring tissues (Halliwell, 1991), while l ip id peroxidation 
products, such as aldehydes, are responsible for pro te in 
modifications and eliciting oxidative cytotoxicity at distant tissues 
(Easterbauer, 1990). So an insufficiency in antioxidant defense 
wi l l render tissues more susceptible to oxidative challenge. Thus, 
enhancement of our antioxidant defense may help to prevent 
disease induced by overwhelming oxidative stress or to l imi t and 
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attenuate cellular injuries caused primarily by other means (Bast, 
A. etal, 1991). 
In contrast to antioxidant defense, the immune system 
operates at cellular level. A number of organs, such as thymus, 
spleen and gut-associated lymphoid tissue, and cell types such as 
lymphocytes, phagocytes and granulocytes, have evolved to 
recognize micro-organisms and the non-selves such as tumours 
and transplants. Their ultimate objective is to eliminate them with 
the help of serum factors such as complements. The effector 
mechanism for the elimination of non-self is not specific. Thus 
when the recognition of non-self does not function properly, the 
effector mechanism can cause damage to the host, as manifested 
in auto-immune disease and allergic responses. Nevertheless, 
pharmaco log ica l enhancement of immune responses 
( immunomodulat ion) only affect the intensi ty of immune 
responses, either enhancement or suppression, but not the 
specificity. Thus the chance to develop auto-immune disease and 
allergy w i l l not be increased by immunomodulatory drugs, 
provided that the recognition of non-self and the regulation 
mechanism funct ion properly. On the other hand, i t is well-
established that immunotherapy is effective in treating cancer 
(Roitt et ai, 1989). It is also evident that disease prevails in the 
case of immunodeficiency such as AIDS. Therefore, enhancement 
of immune responses seems to be beneficial to the host. 
In conclusion, enhancement of antioxidant defense and 
immune responses can increase the body resistance to disease. 
Since the reported biological activities of Ganoderma lucidum have 
already indicated the possibility of intervention on the immune 
system and the antioxidant system, i t is interesting to know 
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whether Ganoderma lucidum can really enhance these body 
defenses, which serve as the objective of this thesis work: to 
further characterize the biological activities of Ganoderma lucidum 
with respect to antioxidant defense and immune functions. 
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Chapte r 2 
Mater ia ls and Methods 
2.1 Cell culture reagents 
2.1.1 Preparation of RPMI-1640 medium 
Modif ied RPMI-1640 powder (supplemented w i th N-[2-
hydroxyethyl]piperazine-N'-[2-ethaiiesulphonic acid], HEPES) was 
purchased f rom Sigma. The powder was dissolved in 1 l i t re of 
double-distilled water, and the solution was supplemented wi th 2 
g ofNaHCOs and adjusted to pH 7.2-7.4. Sterilization was done by 
fi l tering through 0.45 urn Mill ipore HV filter, wi th the addit ion of 
1 % (v/v) penicillin-streptomycin (Sigma). 
2.1.2 Preparation of fetal calf serum (FCS) 
PCS was purchased from Gibco and was stored at -20°C in 50 
ml al iquot un t i l 'use. FCS was used as a supplement to RPMI 
medium (in a f inal concentration as 10 % (v/v)) for cell culture, 
and FCS was heat-inactivated by incubating at 56°C for 30 
minutes before use. 
2.1.3 Preparation of phosphate-buffered saline (PBS) 
PBS was prepared by dissolving 8.0 g of NaCl, 0.2 g KCl, 1.15 
g of Na2HP04 and 0.2 g of KH2PO4 in 1 l i tre double-distilled water. 
The solut ion was steril ized by autoclaving at 121。C for 30 
minutes. 
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2.14 Mitogen and test samples 
Concanavalin A (Con A) was purchased f rom Sigma and 
p repared i n PBS at a concen t ra t ion of 1 m g / m l . 
Lipopolysaccharide (LPS, f rom Salmonella minnesota R5, Rc 
mutant) was also purchased f rom Sigma and dissolved in double-
dist i l led water at a concentration of 1 mg/ml . The mitogen 
solutions and test samples (fractions f rom Ganoderma lucidum 
dissolved in plain RPMI) were sterilized by fi ltering through 0.45 
|im Mill ipore HA filter. 
2.15 Trypan blue exclusion test 
Trypan blue (Sigma) was dissolved in PBS at a f inal 
concentration of 0.1 % (w/v) and fi ltered. An aliquot of cell 
suspension (10 \xl) was mixed wi th an equal volume of trypan 
blue solution. After mixing, the unstained viable cells were 
counted by a haemocytometer. 
2.16 Liquid scintillation counting 
Scintillant was prepared by dissolving dimethyl- l ,4-bis(2-
(5-phenyloxazol))benzene (POPOP) (0.02 % (w /v ) ) , 2,5-
diphenyloxazole (PPO) (0.4 % (w/v)) and Tri ton X-100 (33 % v /v ) 
in toluene (Merck). The preparation was stirred overnight before 
use. Aliquots of 2 ml scinti l lant were added to counting vials 
containing samples (e.g. discs of f i l ter paper f rom cell harvester), 
and the vials were then vortexed and counted by a Beckman LS-
1801 p-counter. 
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2.2 Animal care 
Female BALB/c mice and C57BL/6 mice of 6-8 weeks old 
weighing 20-25 g were used in animal experiments. Animals were 
maintained on a 12-hour light-dark cycle at approximately 22°C 
and allowed food and water ad libitum. 
2.3 Fractionation of Ganoderma lucidum extracts 
Dried Ganoderma lucidum (antler form) was purchased 
f rom an authenticated source in South Korea. Fresh Ganoderma 
lucidum (circular pileus form) was collected on the campus of 
CUHK. The whole plant of Ganoderma lucidum was cut into small 
pieces and extracted wi th hot dist i l led water at 100。C. The 
substances obtained after lyophilization of the crude water extract 
were designated as GLW or CUGLW (for the CUHK sample). GLW 
was re-dissolved in distil led water and fi l tered to remove debris 
(Whatman qualitative 1 f i l ter paper), then i t was added to 5 
volumes of cold ethanol. Precipitates were collected by f i l t rat ion 
(Whatman qualitative 1 f i l ter paper) after 3 hours and the 
precipitated fraction was designated as GLppt (or CUGLppt), while 
the substances remained in the filtrate were designated as GLE (or 
CUGLE). GLppt was redissolved in distil led water and applied to 
DEAE-cellulose (Pharmaicia). The fraction eluted wi th disti l led 
water (pH7) were designated as GLl (or CUGLl). The retained 
fraction was eluted by 1 M NaCl. After desalting wi th Sephadex 
G25 (Pharmacia) column, the f ract ion thus obtained was 
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designated as GL2 (or CUGL2). The fractionation scheme is shown 
in Figure 2.1. 
2.4 Carbon tetrachloride (CCI4 )- induced hepatotoxicity in mice 
2.4.1 Pretreatment scheme and CCI4 treatment 
C57BL/6 mice were treated intragastrically wi th CCI4 at a 
dose of 1.25 ml /kg body weight; CCI4 was dissolved in olive oi l at 
a concentration of 5.9% (v/v). Control animals were given an equal 
volume of olive oi l (vehicle). Before the CCI4 administrat ion, 
animals were treated orally with fractions of Ganoderma lucidum 
(dissolved in distilled water at a concentration of 10 mg/ml unless 
otherwise specified) at a daily dose of 12.5 mg/mkg body weight 
for 8 days. Control animals were given intragastrically wi th an 
equal volume of disti l led water. Al l treatments were conducted 
between 1000 and 1100 hour to minimize possible variations in 
animal response owing to circadian rhy thm. Animals were 
sacrificed 24 hours after CCI4 treatment by decapitation, which 
allowed the collection of blood sample. Hepatic tissue was excised 
f rom a designated region of the liver. 
2.4.2 Preparation of liver homogenates 
Tissue sample from a designated part of the liver was placed 
in ice-cold 50 mM Tris[hydroxymet:hyl]-aminomethane (Tris)-O.l 
mM ethylenediamine tetraacetic acid (EDTA), pH7.6 (10 % (w/v)) 
and homogenized using two 15 second bursts of Kinematica PCU-2 
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and extracted with distilled 
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for 4 hrs 
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GL2, CUGL2 
Figure 2.1 Fractionation scheme of Ganoderma lucidum 
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polytron homogenizer at 13500 rpm. A 10 second interval was 
allowed between two bursts in order to avoid overheating. 
2.4.3 Biochemical assays for assessing hepatotoxicity 
2.4.3.1 Determination of plasma alanine aminotransferase 
(ALT) 
Plasma ALT activity was measured by ALT diagnostic k i t 
purchased f rom Sigma. An aliquot (100 [xl) of properly di luted 
plasma sample was added to 1 ml ALT assay reagent in.a cuvette, 
and the reaction was monitored by measuring the changes in 
absorbance at 340 nm for 6 minutes. Enzyme act iv i ty was 
estimated using an extinction coefficient for NADPH at 340 nm of 
6.22 X 103M-]cm-i and expressed as U / L 
2.4.3.2 Determination of tissue glutathione (GSH) content 
An aliquot (0.2 ml) of tissue homogenate was combined with 
0.2 ml saline (0.9 % NaCl (w/v), followed by the addition of 0.1 ml 
cold 25% trichloroacetic acid (TCA) (w/v). After centrifugation at 
4000 rpm for 10 minutes at 4。C’ an aliquot of 0.2 ml supernatant 
was obtained and added to 1 ml phosphate buffer (0.1 M, pH 8). 
The colour reaction was init iated by adding 50 [il 5,5'-dithio-bis-
(2-nitrobenzoic acid) (DTNB) (Sigma) solution (3 mM, prepared in 
the same phosphate buffer)and absorbance at 412 nm of the 
reaction mixture was measured after 10 minutes. The GSH content 
was estimated f rom a calibration curve using GSH as standard 
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(Sigma) (Akerboom and Sies, 1981) and was expressed as |imole/g 
tissue. 
2.4.3.3 Depletion of tissue GSH in liver homogenates by tert-
butylhydroperoxide (tBHP) 
Peroxide-induced GSH depletionwas measured byin vitro 
incubation of tissue homogenate wi th tBHP. Reaction mixtures, 
containing 0.2 ml of liver homogenates and 0.2 ml saline or tBHP 
(0.1 mM f inal concentration), were incubated at 37。C for 30 
minutes. The reaction was terminated by adding 0.1 m l of 25 % 
TCA，and the GSH content was measured as described in the 
previous section. 
2.4.3.4 Determination of tissue malondialdehyde (MDA) 
content 
Tissue MDA content was determined according to the 
procedure modified'from a method described in Wade and van Rij 
(1988). Assay mixture contained 1 ml cold 0.67% thiobarbituric 
acid (TBA) (Sigma) solution ( in 25% TCA), 1 ml 10 % tissue 
homogenate, 0.45 ml dist i l led water, 50 \xl 90 mM butylated 
hydroxy toluene (Sigma) (dissolved in isopropanol) and 0.5 ml 4 
m M ferric chloride (dissolved in 0.9% saline). The reaction was 
init iated by incubating the mixture at 90。C for 30 minutes. After 
cooling, 4 ml of n-butanol was added. With vigorous mixing by 
vortex and subsequent centrifugation at 2000 rpm for 5 min., the 
butanol layer was taken for the measurement of absorbance at 
532 nm and 453 nm. Tissue MDA content was estimated f rom a 
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c a l i b r a t i o n curve us ing ac id h y d r o l y z e d 1,1,3,3-
tetraethoxypropane (Sigma) as standard. 
2.5 Preparation of murine hepatocytes 
Murine hepatocytes were prepared by a method adopted 
f rom the method of Berry and Friend (1969) which was originally 
developed for isolating rat hepatocytes (see Figure 2.2). 
2.5.1 Liver perfusion 
BALB/c mice was anaesthetized by ether. The abdominal 
cavity was opened, and the posterior vena cava and the hepatic 
portal vein (1.5 cm away f rom the liver) were tied. The hepatic 
portal vein was then cannulated and the liver was perfused with 
EGTA perfusate (Krebs-Henseleit solution: NaCl 118 mM, KCl 4.7 
mM，KH2PO4 1.2 mM, NaHCOs 25 mM, pH 7.2, supplemented with 
5.6 mM glucose and 5 mM ethylene glycol-bis-(p-aminoethyl 
ether)N,N,N',N'-tetraacetic acid (EGTA)). The perfusate was 
saturated with 95 % O2/5 % CO2 and maintained at 37°C. The flow 
rate was so adjusted that i t d id not lead to excessive swelling of 
the liver .After 10 - 15 minutes, the perfusate was changed to Ca2+ 
perfusate (Krebs-Henseleit solution supplemented wi th 3 mM 
CaCl2, 1.2 mM MgS〇4 and 5.6 mM glucose) with the addit ion of 1 
m g / m l collagenase (type I f rom crude extract f rom Clostridium 
histolyticum, Sigma). The f low rate was reduced by half and 
perfusion was continued for about 1 5 - 2 5 minutes unt i l the liver 
appeared to be distintegrated beneath the capsular membrane. 
The liver was then removed from the corpse and immersed in 10 
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Figure 2.2Diagranimatic presentation of the setup of liver 
perfusion 
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ml incubation medium (2 % bovine serum albumin (BSA), 1 mM of 
glutamate (acid form, Ajax), glycine (Ajax) and methionine (Ajax) 
added to the Ca2+ perfusate) 
2.5.2 Isolation of hepatocyte 
The perfused liver was torn and dispersed in the incubation 
medium wi th two pairs of forceps, and the result ing tissue 
suspension was kept at 37°C for 10 minutes wi th gentle shaking. 
It was then fi ltered through a double layered cheese cloth. Viable 
hepatocytes were then obta ined by densi ty grad ient 
centxifugation according to Pertoft e ta i (1980). The fi ltrate (4 ml) 
was layered on the top of 16 ml working Percoll® (Percoll® stock 
obtained f rom Pharmacia of 1.129 g /ml was diluted wi th Krebs-
Henseleit solution to give a resulting solution of 1.065 g /m l and a 
proper osmolal i ty about 300 mosm) in a 40 ml polycarbonate 
centrifuge tube. After centrifuging at 35000 rpm for 15 minutes 
at 4°C (Beckman L7-55 ultracentrifuge), viable hepatocytes were 
separated f rom erythrocytes and dead hepatocytes. Hepatocytes 
were then collected and washed wi th incubation medium for 3 
times. Trypan blue exclusion test was performed to determine the 
percentage of viable cells ( > 90 % viable cells were required), and 
the cell density was adjusted to 1 x ICK) cell/ml. 
2.5.3 Incubation protocol 
Isolated hepatocyte suspension (1 x 106 ce l l /ml ) was 
preincubated at 37°C in a water bath. Fractions f rom Ganoderma 
lucidum prepared in incubation medium were added to the cell 
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suspension, resulting in the di lut ion of the cell density to 5 x 10^ 
cell/ml. Phorone (Sigma, 50 \iM final concentration) or menadione 
(Sigma, 2-methyl-l,4-naphthoquinone, 50 |iM final concentration) 
in dimethyl sulphoxide (DMSO) was added at a final concentration 
of DMSO not exceeding 1% (v/v) , while the control tubes were 
given with equal volume of DMSO. After 30 minute incubation at 
37°C wi th gentle shaking, the hepatocytes were spun down by 
centrifugation at 1000 rpm for 1 minute. The supernatant was 
obtained for the determination of ALT activity as described 
earlier. 
2.5.4 Determination of cellular glutathione by HPLC method 
Cell pellets obtained after centrifugation of the hepatocyte 
suspension were washed wi th Krebs-Henseleit solution for 3 
times. The pellets were then resuspended in distil led water, and 
the cells were lysed by sonication (Branson 321 ultrasonic 
cleaner) in ice for 10 minutes. The resulting suspension was used 
for the determination of glutathione content. An aliquot (0.25 ml) 
of 10 % perchloric acid was added to 0.25 ml sample (glutathione 
standard (Sigma) or the hepatocyte lysate) for deproteinization. 
The precipitate was removed by centrifugation at 2000 rpm for 5 
minutes, and 0.5 ml supernatant was obtained. lodoacetic acid 
(lAA) (50 III) (Sigma) and 0.45 ml K〇H (2 M)-KHC03 (2.4 M) were 
added to the supernatant. The reaction mixture was kept in dark 
for 15 minutes before the add i t ion of 1 m l 1 % 2,4-
dinitrofluorobenzene (FDNB) (Sigma, prepared in ethanol). The 
result ing mixture was kept in dark overnight before HPLC 
analysis (Mertens etal, 1991). 
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2.6 Preparation of splenocytes and lymphocytes 
2.6.1 Isolation of murine splenocytes 
Spleens f rom female BALB/c mice were removed aseptically 
and minced w i th a pair of scissors in RPMI medium. Tissue 
particulates were fi l tered by a sterilized 60 mesh stainless steel 
gauze. Cell suspension (4-5 ml) was obtained and was then 
layered carefully onto 4 ml of Ficoll-Paque® solution (Pharmacia). 
Af ter centr i fuging at 2000 r p m for 7 minutes . at room 
temperature (about 25°C), splenocytes were obtained f rom the 
interface of RPMI medium and Ficoll-Paque®, and they were 
washed twice wi th RPMI medium and then resuspended in RPMI 
medium supplemented wi th 10 % heat-inactivated fetal calf 
serum (FCS) (Gibco) at a cell density of 1 x 10^ cell/ml. Viable cells 
were counted by Trypan Blue exclusion test as described earlier. 
2.6.2 Mitogenic assay by measuring 3H-thymidine uptake 
The mitogenic reponse of the splenocytes was determined 
by measuring the increase in DNA synthesis, as indicated by 3H-
thymidine uptake. Test samples were dissolved in RPMI medium 
and the resulting solution was fi l tered through 0.45 [im Mill ipore 
HA f i l ter . An al iquot (100 [xl) of cell suspension (7.5 x l O 
cell/ml)were incubated with test sample (final volume 200 |il) in a 
flat-bottomed 96-well culture plate (Corning) for 48 hours at 37。C 
in a humid i f ied atmosphere containing 5 % CO2 in air ( C O 2 
incubator, NuAire). The culture was then pulse-labeled for 6 hours 
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wi th [methyl-3H]thymidine (Amersham,2.0 Ci /mmol) at 0.5 ^iQ 
per well. The cells were harvested wi th a cell harvester (Dynatech, 
Automash 2000) using glass microfibre filters (Whatman), and the 
radioactivity was counted by l iquid scintil lation method. 
2.6.3 B cell- and T cell- enrichment in splenocyte 
preparation 
Splenocytes were prepared in a cell density of 1 x lO? 
cel l /ml . Monoclonal antibodies specific against mur ine splenic T 
(anti-Thy-1.2 IgM, Serotec) and B cells (anti-mouse B cell-antigen 
LR-1 IgM, Serotec) were added in proper di lut ions (1:5000 for 
Ant i -Thy-1 and 1:10000 for Anti-mouse LR-1) to splenocyte 
cultures, which were then incubated at room temperature for 10 
minutes. The cells were then washed 4 times and resuspended 
wi th plain RPMI medum. Guinea pig serum (Serotec) was added as 
a source of complement in a d i lu t ion of 1:20，and the cells were 
incubated at 37°C for 1 hour in the C〇2 incubator. Af ter the 
incubation, cells were washed 3 times and resuspended in FCS-
supplemented RPMI wi th ( in case of enrichment) or wi thout ( in 
case of depletion) adjusting the number of viable cells by Trypan 
Blue exclusion test. The eff iciency of the T cell- and B cell-
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assessed by measuring ^H-thymidine incorporation. 
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(concanava l in A (ConA), f r o m Sigma) and B cel l 
mitogen(lipopolysaccharide (LPS), from Salmonella minnesota R5, 
Rc mutant, Sigma) respectively (see Figure 2.3) 
2.6.4 Isolation of human peripheral blood lymphocytes (HPBL) 
from cord blood 
Heparinzed cord blood was obtained from the obstetric ward 
in Prince of Wales Hospital (PWH). Human peripheral blood 
lyphocyte (HPBL) were prepared according to the method of 
Boyum (1968). The heparinized cord blood was first di luted with 
an equal volume of plain RPMI medium. An aliquot (20 ml) of 
di luted cord blood was then layered carefully onto the surface of 
25 ml Ficoll-Paque (Pharmacia) placed in a plastic centrifuge tube 
and centr i fuged at 2000 r p m for 20 minutes at room 
temperature. After centrifugation, the lymphocyte-containing 
layer at the interface was collected. The cell suspension was 
washed wi th plain RPMI medium 3 times before use. Viable cells 
were counted by Trypan Blue exclusion Test. 
2.7 Chromatographic methods 
2.7.1 Fast Protein l iquid Chromatography (FPLC) wi th Superose 12 
column 
The High Performance Liquid Chromatography (HPLC) 
system f rom LKB-Pharmacia was employed for the FPLC analysis. 
Gel-filtration was performed on Superose-12 column (Pharmacia) 
(0.75 X 30 cm; fractionation range: 10'-3 x 10' dalton). The column 
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was equilibrated and eluted wi th 150 mM NaCl, 50 mM sodium 
phosphate, pH 7.0 (for sulphate determination, the buffer was 
changed to 150 mM NaCl, 50 mM Tris at pH7.5) at a flow rate of 
0.4 ml /minu te . Molecular weight markers (al l f rom Sigma), 
、 
i n c l ud ing p - lac tog lobu l in (M.W.35000), cy tochrome C 
(M.W.12400), aprotinin (M.W.6500) and vitamin B n (M.W.6500), 
were used for molecular weight estimation of test sample, wi th 
blue dextran 2000 (Pharmacia) for the measurement of void 
volume. 
2.7.2 Removal of lipopolysaccharide (LPS) with Detoxi Gel 
Detoxi-Gel Endotoxin Removing Gel (Detoxi-Gel) purchased 
f rom Pierce was packed into a mini-column of 1 ml bed volume. 
The column was equilibrated and eluted with 0.1 M ammonium 
bicarbonate buffer (pH 7.8) at a flow rate of 0.5 ml per minute. 
LPS standard (from Salmonella miimesota R5, Rc mutant, Sigma) 
and test samples were prepared in bicarbonate buffer, and a 
sample volume- of 0.5 ml was applied to the column. Three bed 
volumes were collected and the resulting 6-fold di luted sample 
was further di luted wi th FCS-supplemented RPMI medium and 
steril ized by f i l ter ing through 0.45 \xm Mi l l ipore f i l ter before 
adding to the cell culture for mitogenic assay. 
2.7.3 Desalting by Sephadex G-25 
Sephadex G-25 (Pharmacia) was packed in a glass column of 
0.75 cm X 25 cm and equilibrated wi th disti l led water. Samples 
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were applied in a volume of 2 ml and collected as a fraction 
eluted at void volume (as determined by blue dextran 2000). 
2.7.4 Determination of FDNB-conjugated GSH and GSSG by HPLC 
reverse-phase chromatography 
HPLC reverse-phase chromatography with a Nucleosil 120-7 
NH2 column was employed to analyze reduced glutathione (GSH) 
and oxidized glutathione (GSSG), in which their FDNB derivatives 
eluted at characteristic elution times. Solvent A was consisted of 
methanol (HPLC grade, Riedel-de-Haen)-water (4:1 (v/v)). Solvent 
B was obtained by dissolving 54.4 g anhydrous sodium acetate in 
25 ml double distilled water, 75 ml glacial acetic acid and 400 ml 
solvent A. The column was equilibrated wi th 25 % solvent B at a 
f low rate of 1 ml /minute . Sample (50 pi) was applied w i th 
isocratic elut ion of 25 % solvent B for 4 minutes. Then the 
percentage of solvent B was increased to 95 % in 10 minutes. 
After maintaining at 95 % for 5 minutes, the percentage of solvent 
B was decreased back to 25 %, and this composit ion was 
maintained for 5 minutes unt i l chromatographic analysis was 
completed. GSH and GSSG standards (Sigma) were eluted at 19 
minutes and 21 minutes, respectively, wi th baseline separation in 
case of co-injection (see Figure 2.4). Both GSH and GSSG content in 
the sample can be estimated by measuring the peak height in the 
chromatogram, using standard calibration curves (see Figure 2.5). 
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Figure 2.4 Elution profiles of FDNB derivatives of GSH and GSSG 
37 
r 
12000 -j — 7 
/ • GSSG / 10000 - ^ ^ / 
A GSH Z 
8000 一 / 
! 6000 - Z 
^ 4000 _ Z • z 
2000 - J ^ 
X . 口 . . . 
0 - K ‘ 1 ‘ 1 ‘ 1 ‘ 1 ‘ 1 ‘ 
0 20 40 60 80 100 120 _ | 
glutathione equivalent 
Figure 2.3 Standard curves for determination of GSH and GSSG by 
HPLC method 
Glutathione equivalent refers to the amount of GSH or GSSG in nanomoles. Peak height was estimated by computation. The peak signals of GSSG at 10 and 20 nmoles were not able to be detected. 
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2.8 Measurement of in vivo antibody production 
2.8.1 Immunization and pretreatment scheme 
Female BALB/c mice in groups of five were immunized with 
2 X 106 sheep red blood cells (SRBC) (Serotec) in phosphate-
buffered saline (PBS) (0.1 ml) by intraperitoneal injection. Thir ty 
minutes pr ior to immunizat ion, mice were intraperi toneal ly 
injected wi th test samples or PBS (as control). The mice were 
sacrificed 5 days after immunization (unless otherwise specified) 
and the spleens were removed for the preparation of splenocyte 
suspension. 
2.8.2 Direct plaque assay 
Ant ibody-forming cells were enumerated based on the 
Cunningham's modification of the method of Jerne and Nordine 
(1963). Splenocytes were prepared as described earlier, and 
aliquots of 100 |il cell suspensions (with a cell density of 1 x 10^ 
viable cel l /ml as indicated by trypan blue exclusion test) were 
mixed wi th 50 |il 10 % (v/v) SRBC in RPMI medium and 50 
guinea pig serum as a source of complement which was pre-
absorbed with SRBC. The resulting mixture (50 }il) was loaded into 
a Cunningham's chamber, which was then sealed by dipping into a 
melted paraff in wax solution and incubated in horizontal position 
at 37'C for 1 hour. The number of plaque forming cells (PFC) were 




2.9 Biochemical analysis 
2.9.1 Determination of protein content 
Protein content was determined by the method of Bradford 
(1976), using Bio-Rad prote in assay reagent. Bovine serum 
albumin (BSA) f rom Sigma was used as standard. Sample was 
prepared at a concentration of 1 mg/ml in double-distilled water, 
and was then mixed wi th 4 volumes of 5-fold diluted dye reagent 
concentrate. Absorbance at 595 nm was measured after 10 
minutes. 
2.9.2 Determination of hexose content 
Hexose content in polysaccharides was determined by 
an throne/sulphuric acid method, using dextran (clinical grade, 
Sigma) as standard. Sample (0.2 ml) prepared in disti l led water 
was combined with 0.2 ml 12 N HCl and 20 90 % formic acid. An 
al iquot of an throne reagent (1.6 ml) (freshly prepared by 
dissolving 20 mg of an throne (Sigma) in 100 ml of 80 % sulphuric 
acid) was added, and the reaction mixture was heated in boil ing 
water bath for 12 minutes. After cooling, the reaction mixture was 
vortexed and then sonicated in a Branson 321 ultrasonic cleaner 
to disperse the air bubbles. Absorbance at 630 nm was measured. 
2.9.3 Determination of uronic acid content 
Uronic acid was determined according to the method of 
Bitter and Muir (1962)，using glucuronic acid (Sigma) as standard. 
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Sample and standard solution were prepared in disti l led water 
saturated with benzoic acid. Aliquots (1 ml) of sodium tetraborate 
decahydrate in concentrated sulphuric acid were added in tubes 
placed in a rack and allowed to cool in an ice-bath. Sample 
solution (0.2 ml) was carefully layered on the sulphuric acid 
reagent. The reaction mixture was mixed wi th constant cooling, 
and then heated for 10 minutes in a boiling water bath. After 
cooling, an aliquot of carbazole reagent (0.2 ml) (0.125 % (w/v) 
carbazole in absolute ethanol ) was added, and the reaction 
mixture was heated in boiling water bath for 15 minutes. After 
cooling, absorbance at 530 nm was measured. 
2.9.4 Determination of sulphate content 
Sulphate content was measured according to the method of 
Dodgson (1962), using potassium sulphate as standard. Gelatin 
solution was prepared by dissolving 0.2 g gelatin (Sigma) in 40 ml 
of hot water (6070。C). This preparation was allowed to stand for 
at least 6 hours at 4。C. Barium chloride-gelatin reagent was 
prepared by adding 2 g of barium chloride in the semi-gelatinous 
gelatin solution, and the resulting cloudy solution was allowed to 
stand for 2-3 hours before use. Test sample was dissolved in 6 N 
HCl, and 0.4 ml of sample was transferred into a glass tube which 
was then sealed in an oxy-gas flame and kept in an oven at 105-
110。C for 5 hours. After cooling, an al iqout of 0.1 ml acid 
hydrolysate was transferred to a tube containing 1.9 ml of 4 % 
trichloroacetic acid (TCA). Barium chloride-gelatin reagent (0.5 ml) 
was added and the reaction mixture was mixed and allowed to 
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stand for 10-20 minutes at room temperature. Absorbance at 500 
nm was measured. 
2.9.5 Determination of hexosamine content 
Hexosamine content was measured according to the method 
of Belcher (1954), using glucosamine and galactosamine (Sigma) as 
standards. Test sample was dissolved in dist i l led water and 
hydrolysed with 6 N HCl at 100。C for 6 hours. After neutralizing 
wi th NaOH, 0.5 ml of acetylacetone reagent (4 % acetylacetone in 
0.625 M NazCOs (v/v)) and 1 ml distilled water was added to 0.5 
ml acid hydrolysate. The reaction mixture was then mixed and 
heated in boil ing water bath for 10 minutes. After cooling, an 
aliquot of 2.5 ml absolute ethanol was added and the reaction 
mixture was heated to 75'C in a water bath for 5 minutes. An 
aliquots of 0.5 m l Ehrlich's reagent (1.6 g re-crystallized p-
dimethylaminobenzaldehyde (Tokyo Kasei Kogyo) in 30 ml 12 N 
HCl) was added and the reaction mixture was heated at 75°C for 
30 minutes. After cooling, an additional 2.5 ml of absolute ethanol 
was added and absorbance at 520 nm was measured 
2.10 Statistical Analysis 
Data are given as arithmetic mean and standard deviation 
unless otherwise specified. Data f rom plaque forming cell assay 
are given as geometric mean and standard error, because the 
prol i ferat ive response of cells to the antigen occurs i n an 
exponential manner. Comparison between groups were done by 
Student's t-test to assess specific group difference at P < 0.05. 
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- y x � I l ( x - x / 
X = ， S.D. = 1 ^^—— 
n I n - 1 
x= arithmetic mean 
^ x 二 sumof all values of X 
n = number of sample 
X = value of each sample 
S.D.= Standard deivation 
n 
S'ogXi SD 
g=n/x,,x2,...,x, or log g = ， S.E= 
g = geometric mean 
Xj = values of x 





3.1 Extraction and fractionation of Ganoderma lucidum 
Yields of 8.68 % (antler form) and 3.7 % (fresh circular 
pileus) (w/w) of water extract (GLW and CUGLW, respectively) 
were obtained by extracting Ganoderma lucidum i n boiling water. 
Upon cold ethanol precipitation, about 60 % of the crude extract 
(GLE or CUGLE) remained soluble in ethanol. Approximately 40% 
of the precipitate was retained by DEAE cellulose when water at 
neutral pH was the eluant. This negatively charged fract ion was 
eluted wi th 1 M NaCl and was desalted by Sephadex G-25 column 
as described in Materials and Methods，with a f inal yield of 0.53 % 
(GL2) and 0.12 % (CUGL2) (w/w) w i th respect to the raw 
materials. The Ganoderma lucidum sample collected on the 
campus of CUHK gave a relative percentage yield similar to the 
sample obtained f rom South Korea (Table 3.1). For example, 
ethanol-soluble fractions (GLE and CUGLE) were present in larger 
amounts than the precipitate fractions (GLppt and CUGLppt), while 
the negat ively charged f ract ions (GL2 and CUGL2) were 
consistently of lower yield than the unretained fractions on DEAE-
cellulose (GLl and CUGLl). I t seems that Ganoderma lucidum 
sampled f rom dif ferent sources roughly contain similar bulk of 
constituents. However, biochemical analyses on pro te in and 
hexose content (Table 3.2) showed that the CUHK sample 
contained generally higher hexose content and lower prote in 
























































































































































































































































































































































































































































































































































































the nuances in biological activities between the fractions obtained 
f rom CUHK sample and Korean sample. 
3.2 Hepatoprotective effect of Ganoderma lucidum 
fractions against CCU-induced hepatotoxicity 
3 .2 .1 Hepatoprotec t ion of Ganoderma lucidum 
fractions 
As described in Materials and Methods, C57BL/6 mice were 
pretreated wi th Ganoderma lucidum fractions and a sublethal 
dose of carbon tetrachloride (CCI4) was given 24 hours before 
assay. Plasma ALT activities were significantly elevated in CCI4-
challenged mice, an indication of hepatocellular damage (Figure 
3.1). GLW pretreatment sl ightly (not significantly) protected 
against the CCI4 hepatotoxicity. But GLE pretreatment d id not 
produce any effect. Pretreating mice wi th GLl, GL2, CUGL2 or 
CUGLE fraction protected against CCI4 hepatocellular damage, 
while GLppt, CUGLppt, CUGLW and CUGLl preatments d id not 
produce any protective effect (Figure 3.2). 
3 .2 .2 Effect of Ganoderma lucidum f r ac t i on 
pretreatment on hepat ic ma lond ia ldehyde 
(MDA) level in CCI4-treated mice 
Tissue MDA level was increased in CCI4-treated mice (Figure 
3.3). Pretreatment wi th GLl, GL2 or CUGL2 fraction (but not wi th 
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Figure 3.1 Effect of Ganoderma lucidum fraction pretreatment 
on CCU-induced hepatotoxicity 
C57BLy6 mice in groups of 5 animals were pretreated daily with water 
(Control & CCI4) or Ganoderma lucidum fractions (12.5 mg/kg body weight) 
by intragastric intubation for 8 days. On the 9th day, all except the control 
animals were challenged with 5.9 % carbon tetrachloride (CCI4) in olive oil 
at a dose of 1.25 ml/kg body weight, while the control group was treated 
with ol ive oil. Plasma samples were col lected 24 hours a f t e r the 
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Figure 3.2 Effect of Ganoderma lucidum fraction pretreatment 
on CCU-induced hepatotoxicity (cont'd) 
C57BL/6 mice in groups of 5 animals were pretreated daily with water 
(Control & CCl4) or Ganoderma lucidum fractions (12.5 mg/kg body weight) 
by intragastric intubation for 8 days. On the 9th day, all except the control 
animals were challenged with 5.9 % carbon tetrachloride (CCI4) in olive oil 



































































































































































































































































































hepatic MDA level (Figure 3.3). Since elevation of MDA level is 
indicative of oxidative damage, the hepatoprotective effect of 
Ganoderma lucidum fractions, namely GLl, GL2 and CUGL2, might 
be mediated by antioxidant actions. 
3.2 .3 Effect of Ganoderma lucidum f rac t ion 
pretreatment on hepatic glutathione (GSH) 
level in CCU-treated mice 
CCI4 treatment caused a decrease in hepatic GSH level 
(Figure 3.4). It was found that among the hepatoprotective 
fractions, only GL2 and CUGL2 restored GSH level in CCU-treated 
mice (Figure 3.4). Furthermore, although GL2 could not increase 
the tissue GSH level in unchallenged animals, i t significantly 
increased the GSH level in l iver homogenates prepared f rom 
unchallenged animals following in vitro incubation wi th 0.1 mM 
tert-butylhydroperoxide (tBHP) (Figure 3.5). 
3.3 Effect of GL2 on isolated hepatocytes 
3 .3 .1 P r o t e c t i o n a g a i n s t p h o r o n e - i n d u c e d 
hepatocytotoxicity 
Phorone caused cellular damage in isolated hepatocytes, as 
indicated by the increase in ALT activi ty i n the incubat ion 
medium (Figure 3.6). GL2 was found to be able to inh ib i t the 
phorone-induced elevation of ALT activi ty in the incubation 














































































































































































































































































































































































































































































• • tBHPO.1 mM 
• / / / \ \ \ S 
丨 i t l 
control CCI4 GL2 CCI4 + GL2 
Figure 3.5 Effect of GL2 on the hepatic glutathione (GSH) level 
and the susceptibility of hepatic GSH to peroxide-
induced depletion in control and CCU-treated mice 
C57BL/6 mice in groups of 5 animals were pretreated daily with water (Control & CCI4) or Ganoderma lucidum fractions (12.5 mg/kg body weight) by intragastric intubation for 8 days. On the 9 "� d a y , all except the control animals were challenged with 5.9 % carbon tetrachloride (CCI4) in olive oil at a dose of 1.25 ml/kg body weight, while the control group was treated with olive oil. Animals were sacrificed 24 hours after the administration of 
CCI4. Liver homogenates were prepared as described in Materials and Methods. Hepatic GSH level (no tBHP) was determined by the DTNR method, and GSH depletion assay was performed by incubating liver homogenate with 0.1 mM tBHP at 37�C for 30 minutes. ^ 
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U/L 
1 2 0 - j — 
Y////X [Zl phorone 
100- ^ ^ " T " • no phorone 丁 
H 
control GL2 (100 pg/ml) GL2 (400 pg/ml) 
Figure 3.6 Effect of GL2 on phorone-induced cytotoxicity i n 
isolated hepatocytes 
Isolated hepatocytes were prepared as described in Materials and Methods Phorone was dissolved in dimethyl sulphoxide (DMSO) to give a final incubation concentration of 0.5 mM, with less than 1 % DMSO (v/v). The incubation protocol and sample preparation for ALT determination were also described in Materials and Methods. Data are given as the mean of triplicated samples. 
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treated samples could not return to the control level, even though 
the concentration of added GL2 was increased up to 400 jig/ml. 
3.3 .2 Protection against menadione-induced 
hepatocytotoxicity 
Menadione caused cellular injury in isolated hepatocytes, as 
indicated by a drastic increase in ALT activity in the incubation 
medium (Figure 3.7). GL2 could inhibit menadione-induced 
hepatocytotoxicity, as evidenced by the decrease in ALT activity 
in the incubation medium (Figure 3.7). Cellular depletion of GSH 
upon menadione treatment was also found to be associated wi th 
the elevation of ALT activity in the incubation medium in a time-
dependent manner, wi th preliminary results showing that cellular 
GSH level was restored by GL2 (Figure 3.8). 
3 .4 Immunomodulatory effect of Ganoderma lucidum 
fractions 
3 .4 .1 Discovery of a mitogenic principle from 
Ganoderma lucidum fractions 
It has been reported that depletion of cellular GSH in T 
lymphocytes by buthionine sulphoximine (BSO) can suppress the 
Concanavalin A (ConA)- induced mitogenic response (Haminlos 
and Wedner, 1989). However, some reports suggested that the 
BSO-induced cytostasis did not correlate wi th GSH depletion (Kang 
& Enger，1992). In the present study, menadione was used for 
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Figure 3.7 Effect of GL2 on menadione-induced cytotoxicity in 
isolated hepatocytes 
Isolated hepatocytes were prepared as described in Materials and Methods. 
Menadione was dissolved in dimethyl sulphoxide (DMSO) to give a final 
incubation concentration of 50 \lM, with less than 1 % DMSO (v/v). The 
incubation protocol and sample preparation for ALT determination were • 
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A. Time course of menadione-induced GSH depletion in isolated hepatocytes and increase in ALT activity in the incubation medium. 
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B. Preliminary studies showing GSH content was restored by GL2 in menadione-
treated sample (30 minute incubation).ThG ALT data were given as the mean of triplicated sample. 
Figure 3.8 The relationship between GSH depletion and increased release of ALT into the incubation medium in menadione-challenged isolated hepatocytes 
Menadione (50 |iM) was added to 1 x lO^ cells/ml isolated hepatocytes. The cells were spun down by centrifugation and the supernatant was saved for ALT determination. Pelleted hepatocytes were washed and lysed in hypotonic medium by ultrasonification, and determination of GSH and GSSG were performed using 11 PLC method, as described in Materials and Methods.GSSG content was not detectable for all samples. 
57 
cytotoxic effect was observed in menadione-treated splenocytes, 
as evidenced by the decreased -^H-thymidine uptake (Figure3.9). 
GL2, which could inhib i t menadione-induced GSH depletion in 
isolated hepatocytes, was not able to prevent the toxic effect of 
menadione on splenocytes (Figure 3.9). Nevertheless, GL2 was 
found to induce prol i ferat ion of splenocytes i n the absence of 
menadione (Figure 3.9). This f inding has led us to investigate the 
mitogenic acit ivi ty in Ganoderma lucidum fractions. Screening 
test on various fractions showed that the mitogenic act iv i ty 
resided in the negatively charged polysaccharide-rich fractions 
(GL2 and CUGL2) (Figure 3.10，3.11). But these fractions showed 
no effect on human peripheral blood lymphocyte (HPBL) (Figure 
3.12). Since the mitogenic activity was not demonstrable in crude 
extracts, the presence of ant i -pro l i ferat ive pr inc ip les was 
suggested. This was supported by the fact that lipopolysaccharide 
(LPS)-stimulated prol i ferat ion i n murine splenocytes and Con A-
st imulated p ro l i fe ra t ion i n HPBL were suppressed by co-
incubation wi th the crude extract GLW (Figure 3.13，3.14). Results 
obtained f r om the Korean sample and the local sample of 
Ganoderma lucidum agreed well wi th each other, indicating that 
both the mitogenic acit ivi ty and the anti-proliferative pr inciple 
may be inherent components of the fungi. 
3.4.2 B cell-specific mitogenic activity 
Selective deplet ion of splenic B cells and T cells were 
achieved by antibody-dependent and complement-mediated cell 
lysis as described in Materials and Methods. The efficiency of B 
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Figure 3.9 Effect of GL2 on menadione-treated splenocyte 
preparation 
Proliferative response of splenocytes isolated f rom BALB/c mice was 
assessed by measuring ^H-thymidine incorporation, as described in 
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Figure 3.10 Mitogenic activity of Ganoderma lucidum (Korean 
sample) fractions 
The mitogenic act iv i ty was assessed by measuring 3H - t h ym i d i i i e 
incorporation in splenocytes isolated from BALB/c mice, as described in 
Materials and Methods. Each data is the mean ± S.D. from triplicated 
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Figure 3.11 Mitogenic activi ty of Ganoderma lucidum (CUHK 
sample) fractions 
The mitogenic act iv i ty was assessed by measuring ^^H- thymid ine 
incorporation in splenocytes isolated from BALB/c mice, as described in 
Materials and Methods. Each data is the mean + S.D. from triplicated 
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Figure 3.12 Effect of GL2 on human peripheral blood 
lymphocytes (HPBL) 
%-thymid ine incorporation was measured in HPBL preparat ion f rom cord 
blood, as described in Materials and Methods. Each data is the mean 土 S.D. 
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Figures. 13 Effect of GLW on LPS-stimulated prol i ferat ion in 
murine splenocytes 
The mitogenic act iv i ty was assessed by measuring ^ H - t h y m i d i n e 
incorporation in splenocytes isolated from BALB/c mice, as described in 
Materials and Methods. Each data is the mean + S.D. from triplicated 
samples, and expressed as the percentage of control (i.e. without addition of 
drug). GLW was added at a final concentration of 125 |i g/ml. 
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Figures. 14 Effect of GLW on Con A-stimulated prol i feration of 
human peripheral blood lymphocytes (HPBL) 
The Con A-stimulated proliferation of HPBL was measured by -^H-thymidiiie 
incorporation, as described in Materials and Methods. Each data is the mean 
± S.D. from triplicated samples, and expressed as the percentage of control 
(without addition of drug). GLW was added at a final concentration of 125 
\ig/ml 
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number of viable cells as compared wi th the control) was 
evaluated by the responsiveness of splenocytes to known B cell 
and T cell mitogens (LPS and Con A). The results showed that B 
cel l deplet ion completely abol ished the GL2-st imulated 
proliferation, while T cell depletion only slightly suppressed the 
GL2-stimulated proliferation (Figure 3.15). After the viable cell 
number had been re-adjusted, B cell-enriched splenocytes showed 
a higher responsiveness to GL2 stimulation as compared wi th the 
contro l (Figure 3.16), indicat ing that the GL2-stimulated 
proliferation is B cell specific. 
3.4 .3 Mitogenic activity in Ganoderma lucidum 
d i s t i n g u i s h a b l e f r om p o s s i b l e LPS 
contamination 
3.4.3.1 The use of polymyxin B sulphate 
Polymyxin B sulphate, which binds specifically to the l ip id A 
moiety of LPS, was co-incubated wi th GL2 and LPS in murine 
splenocyte preparation. Although 125 | ig/ml GL2 produced less 
stimulation than 0.1 | ig/ml LPS in the absence of polymyxin B, 
polymyxin B produced less suppression on GL2 mitogenic activity 
(Figure 3.17). It was observed that polymyxin B could completely 
suppressed the LPS-induced s t imu la t ion of splenocyte 
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Figure 3.15 Mitogenic activity of GL2 in T cell-depleted and B 
cell depleted murine splenocyte preparation 
Antibody-dependent complement-mediated cell lysis was employed to 
deplete T or B cell specifically. After selective cell depletion, the number of 
viable cell was not adjusted to the original cell density 5 x 10^ cells/ml. The 
GL2-stimulated proliferation of splenocytes was measured by 3H-thymidine 
incorporation, as described in Materials and Methods. Each data is the mean 
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Figures. 16 Mitogenic activity of GL2 in control (T + B cell) and 
B cell-enriched splenocyte preparation 
Antibody-dependent and complement-mediated cell lysis was employed to 
select ively deplete splenic T cells, and the resulting B cel l -enriched 
preparation was re-adjusted to the original cell density in terms of viable 
cell count (7.5 x 10? cells/ml) by trypan blue exclusion test. The GL2-
stimulated proli feration of splenocytes was measured by ^H-thymidine 
incorporation, as described in Materials and Methods. Each data is the mean 
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Figures. 17 Effect of polymyxin B sulphate on GL2- and LPS-
stimulated proliferation of murine splenocytes 
The mitogenic activity was measured by 3H-thymidine incorporation in 
splenocytes isolated from BALB/c mice, as descr ibed in Materials and 
Methods. Each data is the mean 土 S.D. from triplicated samples. 
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3.4.3.1 The use of Detoxi-Gel 
Both LPS standard and GL2 were eluted through Detoxi Gel 
column, as described in Materials and Methods, and the mitogenic 
activity of the pre-column fractions was compared with the post-
column fractions. It was observed that only a small port ion of 
mitogenic activity of GL2 was lost after passing through the Detoxi 
Gel column, whereas the mitogenic activity of LPS was completely 
removed (Figure 3.18). 
3.4 .3 .3 The combined use of polymyxin B sulphate and 
Detoxi Gel 
Pre-column and post-column fractions of GL2 and LPS were 
co-incubated wi th polymyxin B sulphate in murine splenocyte 
preparation. LPS was almost completely removed by Detoxi Gel 
wi th respect to mitogenic activity, and 10 | ig/ml polymyxin B 
sulphate also attained the same extent of suppression to LPS-
stimulated proliferation. In contrast, the mitogenic activity of GL2 
was not affected by passing GL2 through Detoxi Gel column, and i t 
was less susceptible to polymyxin B suppression (Figure 3.19). 
Thus i t is fair to conclude that GL2 contains a genuine mitogenic 
activity different f rom that of LPS. 
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Figure 3.18 Removal of LPS by Detoxi Gel: Effect on mitogenic 
activity 
Equipotent amounts of LPS (2.4 |ig/ml) and CTL2 (3 mg/ml) in ammonium 
hydrogencarbonate buf fer (pH 7.8) were applied to Detoxi Gel (1 ml bed 
volume) with a flow rate of 0.5 ml/minute. Three bed volumes were 
collected and the diluted samples were calculated to contain 0.4 [ig/m\ LPS 
or 500 |ig/ml GL2 if there were no retention of samples. The mitogenic 
act ivity was measured by n i - thymid ine incorporation in splenocytes 
isolated from BALB/c mice, as described in Materials and Methods. Each data 

































































































































































































































































































































































































































































































































3.5 Enhancement of humoral response to sheep red 
blood cells (SRBC) by the mitogenic GL2 fraction 
It has been reported that co-administrat ion of B cell 
mitogens and immunogens can augment the humoral response 
against immunogens (Diamantstein, 1976). Thus, the ability of GL2 
i n augmenting humora l immune response was examined. 
Enumerat ion of plaque-forming cells (PFC) in splenocyte 
preparat ion was employed to measure the extent of the 
generation of antibodies (specific to act against SRBC) in BALB/c 
mice (see Exhibit 3, 4), as described in Materials and Methods. It 
was found that intraperitoneal (IP) injection of 1 mg GL2 ( in 0.1 
ml saline) was effective in increasing the number of PFC/IO? 
splenocytes up to 30-fold (Figure 3.20). IP injection of GLW, 
CUGLW or GLl could not significantly increase the number of 
PFC/107 splenocytes (data not shown). It was observed that GLl 
was suppressive to antibody formation. IP injection (0.1 ml) of 0.1 
mg/ml LPS was significantly effective in increasing the number of 
PFC. CUGL2 was less active in causing a significant enhancement. 
Intragastr ic dosing of GL2 also d id not show signi f icant 
enhancement of humoral response (Table 3.3). The results indicate 
that enhancement of humoral response is l ikely to be associated 
wi th the B cell mitogenic activity. 
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Exhibit 3 The Cunningham chamber showing the plaques (from 
the control group which had been injected wi th PBS 
before immunization) I H I 
Exhibit 4 The Cunningham chamber showing the plaques ( from 
the treated group which had been injected wi th GL2 
before immunization) 
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• IP injection of PBS 





Day 4 Day 5 
Day a f t e r i m m u n i z a t i o n w i t h 2x 1 0® SRBC 
Figure 3.20 Enhancement of humoral response in BALB/c mice 
by intraperitoneal injection of GL2 
BALB/c mice in groups of 8 animals were intraperitoneally (IP) injected 
with 0.1 ml phosphate-buffered saline (PBS) or GL2 (10 mg/ml) 30 minutes 
before immunization with 2 x ICK) sheep red blood cells (SRBC). Enumeration 
of plaque forming cell (PFC) was performed 4 and 5 days after 
immunization, as described in Materials and Methods. Data are given as 
geometric mean. The vertical error bar is standard error. * denotes 
significant d i f f e rence when compared with control (injection of PBS) 
using Student's t-test. 
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Treatment Number of PFC/107 splenocytes 
I P injection of 0.1 ml PBS# 28 土 11.1 ‘ 
I P injection of 0.1 ml GL2 (1 mg)# 891 ± 283.8 
I P injection of 0.1 ml PBS 27.5 土 43.53 
I P injection of 0.1 ml LPS (10 \xg) 146 土 50.9 
IP injection of 0.1 ml CUGL2 (1 mg) 102.2 土 141.2 
IP injection of 0.1 ml GLl (1 mg) 5 ± 6.46 
Daily intragastric intubation of 0.1 39.26 土 12.3 
ml distilled water for 7 days* 
Daily intragastric intubation of 0.1 63.4 土 44.5 
mlGL2 (1 mg) for 7 days* 
# 11 = 8 
* Mice were immunized 2 days after intragastric GL2 pretreatment. 
Plaque assay was performed 5 days after immunization while the 
intragastric treatment of drugs continued until 1 day prior to assay 
Table 3.3 Effect of various treatments on the humoral response 
to SRBC in BALB/c mice (n = 5) 
Mice in groups of 5 animals were immunized with 2 x 10^ sheep red blood 
cells (SRBC) by intraperitoneal (IP) route. Plaque assay was performed 5 
days after immunization. Data are given as geometric mean and standard 
error, as described in Materials and Methods. 
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3.6 Physical-chemical characterization of GL2 fraction 
3 .6 .1 Estimation of molecular size by HPLC size 
exclusion chromatography with Superose 12 
column 
HPLC using Superose 12 column was performed as decribed 
in the Materials and Methods, using phosphate buffer at pH 7.0 as 
eluant. With reference to molecular weight markers sized f rom 
204 dalton to 35000 dalton, the major peak which eluted at 41.6 
minutes was estimated to have a molecular size about 5700 dalton 
(Figure 3.21, 3.22). The obvious asymmetry of this peak suggested 
that certain small peaks were hidden under the major peak. Peak 
signals were able to be detected during elution time of 30 to 37 
minutes (32.1, 36.2 minutes). In addition, a small peak was eluted 
at void volume (18.3 minutes), and a peak which only showed 
absorbance at 214 nm (with no signal given by absorbance at 280 
nm) eluted at 53.4 minutes. 
• 
3.6.2 Sugar composition of GL2 fraction 
For the sake of comparison, the sugar composition of GLl 
and GL2 were tabulated together in Table 3.4. It was observed 
that uronic acid and sulphate were rich in the negatively charged 
GL2 fraction, while hexosamine was only detected in GLl fraction, 
which is neutral or positive in charge. 
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Figure 3.21 Molecular weight estimation by gel filtration 





































































































































































































































































































































































































3.6.3 Comparison of elution profiles in Superose 12 
with respect to mitogenic activity and sugar 
composition 
The elution profile of GL2 showed that the profile of hexose-
containing fractions was not coincided wi th that of the uronic 
acid-containing fractions (Figure 3.23). It was observed that only 
fractions of molecular size around 5000 dalton contained uronic 
acid in addition to neutral hexose. However, the mitogenic activity 
was neither associated w i th hexose- nor the uronic acid-
containing fractions. However, the ^H-thymidine incorporation of 
the eluted fractions was too low for indicating mitogenic activity, 
probably due to the improper pH (pH 7.0) of the eluant or the 
h igh concentration of phosphate (50 mM). Moreover, since 
phosphate w i l l in te r fe re the assay fo r sulphate, the 
chromatographic condition was changed to Tris buffer at pH 7.5. 
The elution profile of sulphate-containing fraction demonstrated 
that the sulphate content was coincided wi th the mitogenic 
fractions (Figure 3.24). The major mitogenic components were 
eluted at void volume, which might be due to the aggregation of 
polysaccharides i n the new buf fer system. Therefore, the 




y。control ^ig/ml ^^g/mi 
3 0 0 1 8 0 0 " j r 2 0 0 
A m i t o g e n i c activity 
• H e x o s e content 
— O U r o n i c acid content 
r � 遍 ！ 
•S 二 丨 •尝 
、：^^ IJKJ 
0 丄 0 - J ~ ~ I ~ • ~ 1 - 0 
0 10 2 0 30 4 0 50 6 0 7 0 min 
R e t e n t i o n t i m e 
Figure 3.23- Elution profiles of GL2 on Superose 12 column wi th 
respect to hexose content, uronic acid content and 
mitogenic activity on murine splenocytes 
An aliquot (200 \i\) of GL2 (20 mg/ml) was applied to the column, with the 
chromatographic conditions described in Materials and Methods. Hexose 
content was measured by Anthrone method. Uronic acid content was 
measured according to the method of Bitter and Muir (1962). The mitogenic 
activity was measured by ^H-thymidine incorporat ion in sp lenocytes 
isolated from BALB/c mice, as described in Materials and Methods. Each data 









































































































































































































































































































4 ,1 Enhancement of antioxidant status by Ganoderma 
lucidum fractions 
Although previous studies on hepatoprotective activities of 
Ganoderma lucidum suggested that the active principle might be 
triterpenoids (Liu, 1979), the present study showed that the 
polysaccharide fractions may also contribute to hepatoprotection. 
Since hepatoprotect ion is generally studied, by models of 
experimentally-induced hepatotoxicity, this discrepancy may be 
explained by the differences of various experimental models. 
Thus, i t is necessary to define the model of hepatotoxicity pr ior to 
the discussion on the hepatoprotection conferred by Ganoderma 
lucidum fractions. 
It is wel l known that CCI4 hepatotoxicity depends on 
reductive dehalogenation by a specific cytochrome P450 isozymes 
(Recknagel eta/ , 1991). The one-electron reduct ion generates 
trichloromethyl radical, 
C C ^ e _ — — • - c a j f - a _ 
Further reaction of •CCI3 radicals w i th molecular O2 to fo rm 
tr ichloromethyl peroxyl radicals (-OOCCls) occurs very rapidly. 
These free radicals attack methylene carbons of polyenoic fatty 
acids of the membrane phosphol ip ids and in i t ia te l i p i d 
peroxidation. Moreover, covalent binding of CC、cleavage products 
to microsomal l ipids and proteins also occurs. The combined 
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effects of l ip id peroxidation and covalent modification induce the 
onset of structural and functional derangement of the endoplasmic 
ret iculum (ER). A part icular ly important consequence of ER 
damage is the rapid collapse of the capacity to sequester calcium 
ions. The resulting elevation of intracellular calcium level wi l l 
trigger a series of events leading to cell death. It was found that 
drugs (e.g. phenobarbital, propylgallate) metabolized by the same 
metabolic chain in the ER as CCI4 can reduce the toxicity of CCI4 
(Diazani, 1991). So the toxicity of CCI4 depends on its metabolism 
by the cytochrome P450 system. On the other hand, antioxidants 
(e.g. v i tamin E) and metal chelators (e.g. • desferrioxamine) 
attenuate the CClf induced hepatotoxicity by interfer ing the 
progression of l ip id peroxidation; however the covalent binding of 
CCI4 cleavage products to cellular components are not affected. 
Therefore, the hepatoprotection afforded by antioxidants or drugs 
which enhance endogenous antioxidant defense cannot completely 
neutralize all CCVinduced toxicity. Nevertheless, animal model of 
CCVinduced hepatotoxicity was stil l employed for screening test 
for hepatoprotective ant ioxidant pr inciples because of its 
reproducibil ity. 
In order to measure the extent of hepatic damage, the 
measurement of plasma alanine aminotransferase (ALT) served as 
a pr imary biochemical index. ALT are found mainly i n the liver; 
when liver cells are injured, they are leaked out and get into the 
main circulation. Thus plasma ALT activity can be used as specific 
marker for l iver parenchymal in ju ry . However, elevation of 
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plasma enzyme activity may sometimes be caused by altered 
permeability of membranes due to systemic effects of an agent 
rather than specific hepatic injury (Zimmerman, 1974). Therefore, 
i n describing oxidative hepatic injury, measurement of plasma 
enzyme activity should be corroborated by other markers of 
in jury such as histological observations of the liver in jury or 
measurements of markers for oxidative damages such as tissue 
malondialdehyde (MDA) level. Therefore hepatic MDA levels in 
control and CCU-treated animals were also measured in the 
present study. 
MDA is present at in low concentrations in plasma, blood 
cells and the liver in mammals (Schaur et ai, 1991)，due to its 
continuous production and removal. Along wi th other aldehydes 
(e.g. 4-hydroxynonenal), MDA is derived f rom l ip id peroxidation 
as a degradation product of co-3-, co-6-, co-9-polyunsaturated fatty 
acids. Normally, aldehydes generated in vivo can be removed by 
aldehyde dehydrogenase (ALDH) and glutathione S-transferases. 
MDA is preferentially inactivated by ALDH. In rat liver, MDA is 
metabolized by a mitochondr ia l aldehyde dehydrogenase to 
malonic acid semialdehyde, which is decarboxylated and then 
oxidized to form acetate by the main metabolic route (Sui and 
Draper, 1982). 
MDA can react wi th amino groups in proteins, nucleic acids 
and phospholipids, and wi th protein thiol groups. Because of its 
divalent nature, cross-linkings of proteins and nucleic acids are 
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not uncommon. The effects of MDA on enzymes, its toxicity, 
genotoxicity and mutagenicity are likely based on this reactivity 
(Schaur, 1991). 
In the study of hepatoprotection of Ganoderma lucidum 
fractions in animal model of CCl^induced toxicity, elevation of 
plasma ALT level was evident in the CCVchallenged group, and it 
was accompanied with increased tissue level of MDA measured in 
l iver homogenates. This suggests the involvement of oxidative 
reactions in the development of CCl^induced hepatic in jury. It 
was found that the hepatoprotective effect of Ganoderma lucidum 
was contr ibuted by various components. Both GL2 and CUGL2 
showed hepatoprotective activity, thus the negatively charged 
fractions may contain a hepatoprotective principle commonly 
present in Ganoderma lucidum regardless of the source. On the 
other hand, the association of hepatoprotective activity with GLl 
and CUGLE, but not wi th CUGLl and GLE may be due to the 
nuances in the chemical composition in samples f rom different 
sources. For example, GLE contained a significantly lower hexose 
content than CUGLE. As GL l and GL2 were active i n 
hepatoprotection, i t suggests that GLppt should possess activities 
comparable to those of GL l and GL2. The absence of 
hepatoprotective activity in GLppt could be explained by the 
presence of some antagonizing substances which were removed 
during the desalting procedure in preparing GL2. Although four 
fractions of Ganoderma lucidum appeared to be hepatoprotective 
as indicated by plasma ALT levels (GLl, GL2, CUGLE, CUGL2)， 
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CUGLE failed to restore tissue MDA to the control level. So the 
hepatoprotective effect of CUGLE was not affirmed. In contrast, 
GLl, GL2, CUGL2 inhibited the elevation of MDA level upon CCl^  
challenge. They may l imit the production of MDA or accelerate its 
clearance. Since l ip id peroxidation is an auto-accelerating process, 
removal of MDA is less l ikely to catch up the rate of MDA 
generation during the exposure to an oxidative stress. Thus, either 
the inhibi t ion of l ip id peroxidation or the interference on CCl^ 
metabolism may account for the decrease in MDA level. In order 
to assess the possibility of intervention on l ip id peroxidation, the 
glutathione (GSH) status in the liver homogenates was examined. 
It is well-established that GSH plays a key role in supporting 
the antioxidant defense, and extensive l i p id peroxidat ion is 
usual ly associated with an exhaustion of GSH-dependent 
protective mechanism, resulting in a reduced cellular GSH level 
(Saez et a l , 1990). In the present study, only GL2 and CUGL2 
showed marginal restoration of GSH level, while GLl appeared to 
be ine f fec t i ve i n res to r ing GSH level . Since tert-
butylhydroperoxide (tBHP) exert an oxidative challenge to l iver 
homogenates, i t can be used for detecting small difference in 
tissue antioxidant capacity, e.g., the glutathione status. Because 
cellular glutathione level was strictly regulated, GSH status wi l l 
not be obvious unt i l the exposure to an oxidative challenge. It 
explains why GL2 only increased GSH level in the presence of 0.1 
m M tBHP. Thus, the hepatoprotect ive effect of GL2 (and 
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presumably CUGL2) may be associated to an enhanced glutathione 
status, rather than the intervention to CCl^etabolism. 
Further examination on the association of GL2 and enhanced 
GSH status was studied wi th isolated hepatocytes and GSH-
depleting agents such as phorone and menadione. Phorone has 
been shown to be able to deplete cellular glutathione (GSH) 
through conjugation, reaction which can be catalyzed by 
glutathione S-transferases (Wendel et a l , 1990). As a result of GSH 
depletion, metabolic production of reactive oxygen species (R〇S) 
prevails and oxidative damage accumulates, which subsequently 
leads to cell death. On the other hand, menadione induced 
enzymatic depletion of cellular GSH by generating superoxide 
anions (Qf.) through redox cycle (Cadenas etal, 1992). Superoxide 
dismutase rapidly converts O?、into H2O2, which is then reduced to 
water by glutathione peroxidase at the expense of GSH. The 
result ing oxidation of GSH also leads to extensive oxidative 
damage as in the case of phorone-induced depletion of GSH. 
Although GL2 was not very effective in protecting hepatocytes 
f r om phorone-induced toxicity, i t appeared to be able to 
completely antagonize the menadione-induced toxici ty. The 
ineffectiveness of GL2 in neutralizing phorone-induced toxicity 
might be due to the fact that phorone induced a net loss of cellular 
GSH (GSH-phorone conjugates w i l l be exported out of the 
hepatocytes), thus the metabolic activity (energy supply and 
precursors for GSH synthesis) of isolated hepatocytes may not be 
high enough to support the replenishment of cellular glutathione 
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by net synthesis (Berry et ai, 1992). In contrast, menadione-
induced GSH depletion only alters the ratio of GSH/GSSG (Di Monte, 
1984). Thus it is easier to restore the GSH status (i.e. by increasing 
NADPH supply which provides reducing equivalents for the 
regeneration of GSH f rom GSSG). So i t suffices to say that the 
hepatoprotective effect of GL2 may be related to the maintenance 
of cellular GSH level. 
4.2 The significance of enhancement of GSH status 
I t is well-known that GSH exerts a broad spectrum of 
biological activities (Dolphin et a l , 1989). Being an integral 
component for maintaining cellular integrity and functionality, i t 
plays a crucial role in the antioxidant defense system as well as 
detoxification system, and i t also contributes to cellular regulation 
via thiol-disulphide exchange (Gilbert, 1990). 
In addi t ion to the direct scavenging of R〇S wi th GSH 
peroxidase, GSH also helps to regenerate a—tocopherol f rom 
chromaiioxyl radical (vit E.) and vit. C f rom dihydroascorbate by 
the impor t of reducing equivalence, where GSH itself is 
regenerated by GSSG reductase at the expense of reducing 
equivalence f rom NADPH (Freisleben and Packer, 1993). Thus 
glutathione can be considered as one of the common "reducing 
currency" in antagonizing oxidative damage, because both the 
enzymatic and non-enzymatic antioxidants are supported by the 
maintenance of a high ratio of GSH/GSSG. 
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The importance of maintaining high GSH/GSSG ratio is to 
preserve the thiol-disulphide status of cysteinyl residues in 
proteins, which are usually crucial for the proteins to perform 
enzymatic or receptor functions. For example, upon oxidative 
stress which lead to elevation of GSSG, several key enzymes are 
oxidized to form GSH mixed disulphide. Enzymes promoting 
degradation of glucose via the glycolytic pathway are inactivated 
in the form of mixed disulphide, while the activities of enzymes 
reversing glycolysis and promoting pentose phosphate pathway 
are up-regulated. As a result, the relevant metabolic f low is 
directed toward the synthesis of NADPH which serve to reduce 
GSSG and restore the GSH/GSSG ratio (Inoue, 1989). On the other 
hand, several receptor molecules are reported to form mixed-
disulphides wi th GSSG, or that their disulphide linkages can be 
reduced by GSH, which result in alterations in binding affinities. 
NMDA receptor (Leslie et ai, 1991)，insulin receptor (Gilbert, 
1990) and IL-2 receptor (Liang et al，1989) are the examples 
which GSH or GSSG can modify their ligand binding affinities. In 
addi t ion to binding af f in i ty, signal transducing properties 
attributed to the conformational changes of receptor molecules 
can also be affected. In case of intracellular receptors such as I P 3 
receptor, receptor mixed-disulphides formed with GSSG increase 
the receptor sensitivity to I P 3 which leads to modulat ion of 
calcium signal (Renard et ai, 1992). Therefore, i t seems that most 
physiological processes require a sufficiency of glutathione status, 
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Since glutathione takes part in the maintenance of cellular 
integr i ty, pathological insults are usually accompanied wi th 
decreased glutathione level or altered GSH/GSSG ratio, which wi l l 
fur ther weaken the defense against the insults. Thus i t is 
important to maintain glutathione level and GSH/GSSG ratio via an 
intricate network of glutathione metabolism. 
Glutathione is degraded extracellularly, thus degradation of 
glutathione requires the export systems, such as the GSSG export 
system which serves to temporar i ly mainta in intracel lular 
GSH/GSSG ratio during the exposure to extensive oxidative stress 
(Akerboom and Sies, 1989)，the GS-X export system which 
removes inactivated xenobiotics as glutathione S-conjugates 
(Ishikawa, 1992)，and the GSH export system which is mainly 
found in l iver (Ruiz et a l , 1992). Liver seems to be the most 
important organ which actively export GSH, which is considered as 
the major source of plasma glutathione. Extracellular glutathione 
is believed to achieve membrane protection f rom oxidative attack 
and modulate the thiol status of extracellular proteins by the 
format ion of protein mixed-disulphides (Akerboom and Sies, 
1992). With all exported forms of glutathione mentioned above, 
degradation (mainly occurs in kidney) is achieved by the action of 
membrane-bound ectoenzyme y-glutamyl transpeptidase 
(Curthoys, 1990). Thus, i t does not make sense to reduce 
uti l ization as to maintain GSH status. In contrast, enhancement of 
GSH status should be attained through the intervent ion on its 
synthesis and/or regeneration. 
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Glutathione synthesis is a two-step enzymatic process, wi th 
one molecule of GSH being synthesized, two molecules of ATP are 
consumed. The synthesis is catalyzed by successive actions of y-
glutamylcysteine synthetase and GSH synthetase, which catalyze 
reactions 1 and 2 respectively (Meister, 1989)， 
Mg2+ 
L-glutamate +L-cysteine + ATP ^ 、 
L- Y-glutamyl-L-cysteine + ADP + P ^ (1) 
Mg2+ 
L- T-glutamyl-L-cysteine + ATP + glycine ^ � 
G S H + A D P + P i ( 2 ) 
y-glutamylcysteine synthetase catalyzes the rate-determining step 
in GSH synthesis. I t works at sub-optimal activi ty owing to the 
negative feedback of GSH. Although i t has been shown that the 
hormonal regulat ion of GSH synthesis is chief ly acting at the 
transcript ion level of Y-glutamylcysteine synthetase (Lu, 1992), 
the influence of substrate availabil i ty dominates i n most cases. 
Though all of the precursor amino acids are not essential amino 
acids, cysteine is der ived f r o m the essential amino acid 
methionine via the cystathionine pathway which occurs only in 
liver. Glutamate and glycine are present at high plasma levels and 
the amino acid transporters for glycine (system A, ACS) and for 
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glutamate, (e.g.X-AC ) are widely distributed (Guidotti and Gazzola, 
1992). On the other hand, plasma cysteine level is much lower and 
most of them exist in the disulphide form cystine. As a result, for 
those extrahepatic tissues, the extent of cysteine impor t 
profoundly determines the rate of GSH synthesis and thus the GSH 
level (Dalhoff and Poulsen, 1992). It might help to explain the 
d i f ferent ia l effect of GL2 on protect ing hepatocytes and 
lymphocytes against menadione toxicity presumably by enhancing 
cellular GSH status (see Figure 3.8, 3.9), since hepatocytes do not 
require exogenous source of cysteine. Thus, decreases in GSH level 
wi l l f irst relieve the feedback inhibi t ion on y-glutamylcysteine 
synthetase, which results in the acceleration of GSH synthesis， 
provided that the cysteine availabil i ty is also concomittently 
increased. The induction of system X'c (amino acid transporter for 
cystine) activity may contribute to this adaptation in certain cell 
types (e.g. lymphocytes) (Droge and Eck, 1991). However, 
pathological depletions of GSH usually overwhelm the abil i ty for 
the replenishment of GSH, of which cysteine availabil i ty is the 
most l imi t ing. Thus pharmacological interventions aimed at 
maintaining glutathione status are designed to increase cysteine 
avai labi l i ty , such as the use of N-acetyl cysteine (direct 
administration of cysteine is abandoned because of the toxicity of 
cysteine) (Flanagan and Meredith, 1991). However, as also in the 
case of antioxidant therapy, in proposing the pharmacological 
enhancement of glutathione status in treating human diseases, i t 
is important to note the following: 
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1. Antioxidant activity is non-specific. The antioxidant may cause 
damage since some free radical reactions play a physiological 
role. Therefore, delivery of antioxidant to the target tissues 
wi thout interfer ing the others should confer specificity to 
antioxidant therapy. 
2. Most antioxidant can have pro-oxidant action. For example, 
combination of vit. C wi th ferric or ferrous ions causes intense 
oxidation of poly-unsaturated fatty acids. Thus, whether pro-
oxidant act iv i ty is present or not should be taken into 
considerations. 
3. Time frame of antioxidant administration wi th respect to the 
disease stage may affect its efficacy in treating the disease. For 
some pathological conditions, antioxidant administration during 
the course of the disease process is effective, when oxidative 
damages are st i l l reversible. While in other cases such as 
atherosclerosis and cancer, antioxidant supplementation is 
preventive rather than therapeutic. 
Thus, in the development of new therapeutic antioxidants, 
the question of how these compounds are incorporated or 
commensurated wi th the existing antioxidant defense system 
should be addressed (Sies, 1991). Alternatively, enhancement of 
the existing antioxidant defense (e.g. glutathione status) thereby 
providing preventative protection on our body should be a much 
better approach. 
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4.3 Immunomodu la to r y actions of Ganoderma lucidum 
and its impl icat ions 
Mitogen stimulation of lymphocytes in vitro is believed to 
mimic the series of events which occur in vivo following their 
stimulation by specific antigens. In case of B cell, the story is not 
so simple. Proliferation of B cells in vivo is stimulated by antigen 
binding to the membrane-bound immunoglobulin, this process is 
modulated by an array of cytokines and cell-to-cell interactions 
with other immunocytes (Callard, 1990). Usually, proliferation and 
di f ferent iat ion of B cell occur simultaneously after antigenic 
stimulation. However, mitogenic stimulation of B cells in vitro can 
only represent the B cell response to a restricted group of antigen 
thymus-independent antigens (TI), which can be divided into 
two types: TI-1 and TI-2 antigens. Lipopolysaccharide belongs to 
the TI-1 class which can stimulate polyclonal B cell responses in 
the absence of helper T cells and their cytokines. In contrast, TI-2 
antigens, which are polysaccharides composed of mul t ip le 
identical antigenic epitopes, requires small numbers of T cells for 
generating antibody response. Both of them do not elicit isotype 
switching and aff inity maturation, and the stimulated B cells wi l l 
not generate specific immunological memory. Thus, the evolution 
of B cell response to TI antigens is regarded to provide a less 
specific humoral response against bacterial infection since most TI 
antigens are of bacterial origin (Abbas et ai, 1991). On the other 
hand, in vitro use of B cell mitogen usually relies on their 
adjuvant effect on B cell response to cytokines in the absence of 
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antigenic stimulation. However, B cell mitogens have also been 
studied in vivo. It has been reported that all B cell mitogens can 
exert an adjuvant effect to humoral immune response, and the 
enhancement of the immune response can be explained by a "two 
signal hypothesis" certain B cells receive a signal f rom the 
antigen (through membrane-bound immunoglobul in), but the 
inductive stimulus is not completed unt i l a second mitogenic 
signal is delivered to the same cells (Diamanstein et al, 1976). The 
mitogenic signal is normal ly delivered by T cells and their 
cytokines, which would depend on the susceptibil i ty of the 
antigen to antigen-processing, whereas B cell mitogens bypass this 
step and provide the mitogenic signal. Thus, B cell mitogens in 
vivo may play an immunomodulatory role. The present study 
shows that fraction GL2 f rom Ganoderma lucidum contain a B cell 
mitogenic principle which can augment humoral response in mice 
a putative immunomodulatory activity. 
The discovery of a murine B cell mitogen (contained by 
fract ion GL2) in Ganoderma lucidum is novel i n the current 
research on its biological activity, according to a dynamic database 
called NAPRALERT (an acronym for NAtural PRoducts ALERT) 
(NAPRALERT, 1994). The presence of anti-proliferative principles 
were also demonstrated in the crude extract, so this may account 
for the late discovery of the B cell mitogenic principle. Since 
Gram-negative bacteria are ubiquitous, i t is not surprising that 
endotoxins (lipopolysaccharide, LPS) are frequent contaminants of 
biochemical preparations. Thus, precautions are taken to eliminate 
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the possibility of artefacts owing to contamination by LPS. Various 
methods have been tried to distinguish the mitogenic activity of 
GL2 from that of LPS, including the modulation of proliferation by 
co-incubation wi th pro-oxidants and antioxidants such as tBHP, 
GSH, ascorbic acid and Trolox C (a water soluble derivative of 
vi tamin E). The choice of these drugs to intervene GL2-induced 
prol i ferat ion was based on the previous f inding that GL2 can 
enhance antioxidant status, thus its action on B cell might be able 
to be modified by pro-oxidants/antioxidants. However, no matter 
how these drugs act (augmenting or suppressing proliferation), 
GL2-induced proliferation on B cells received the same modulation 
as LPS-induced proliferation. Therefore, polymyxin B and Detoxi 
Gel, which interact specifically to the l ip id A moiety of LPS, were 
employed to suppress or remove the LPS-like activity. The results 
show that GL2 contains a genuine B cell mitogenic pr inciple 
distinguished f rom LPS, and this mitogenic principle may be of a 
fungal origin because of its presence in both CUHK sample and 
Korean sample of Ganoderma lucidum. Physical-chemical 
characterization revealed that the mitogenic principle in GL2 may 
be a sulphated glycan. It is well-known that dextran sulphate is a 
murine B cell mitogen, so the mitogenic principle in GL2 may be a 
natural counterpart of the artificial dextran sulphate. 
Finally, i t should be noted that all murine B cell mitogens 
cannot stimulate human B cells. Preliminary study on GL2 also 
agree w i th this proposi t ion. However, i t was accidental ly 
demonstrated that GL2 can induce pro l i ferat ion on human 
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lymphocytes in the presence of Trolox C (See Appendix 1)(which 
also augments LPS- and Con A-induced prol i feration of murine 
splenocytes, see Appendix 2), thus the possibility of GL2 to exert 
an immunomodulary action on human system cannot be excluded. 
98 
Conclus ions 
Our results show that a negat ively-charged and 
carbohydrate-rich fract ion (GL2) extracted f rom Ganoderma 
lucidum exhibited both hepatoprotective and immunomodulatory 
activities. It was also demonstrated that the hepatoprotection 
afforded by GL2 pretreatment may be mediated by enhancement 
of hepatic glutathione status, whereas the B cell mitogenic 
principle in GL2 may be a sulphated glycan. 
Ganoderma lucidum has long been recognized as a "Fu 
Zheng” drug, which enhances the body defense against disease. 
Current findings regarding Ganoderma lucidum agree well wi th 
this claim because both antioxidant defense system and immune 
system are crucial for body resistance to disease. Moreover, the 
legendary claim that Ling Zhi is an elixir of longevity suggests the 
presence of anti-aging principles in Ganoderma lucidum. Since i t 
has been shown that declines in ant ioxidant defense and 
immunocompetence are major determinants of the aging process, 
Ganoderma lucidum might therefore be effective in attenuating 
age-associated deteriorations of body functions. Further studies on 
the possible interventions in aging process by Ganoderma lucidum 
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